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Alzheimer’s disease (AD) is a progressive, neurodegenerative disease and the most 
common form of dementia. It is characterized by a decline of memory, language, 
problem-solving and other cognitive skills that affect individual ability to perform 
everyday activities. 
The two main neuropathological hallmarks of AD are extracellular deposits of amyloid-
beta (Aβ) in diffuse plaques and plaques containing elements of degenerating neurons 
(neuritic plaques), and neurofibrillary tangles (NTFs) consisting of hyperphosphorylated 
tau protein accumulation inside neurons. Activation of microglia, astrocytes, loss of 
neurons and synapses are also widespread in AD brains.  
Several genes, environmental factors and interactions among genes and these 
components may be involved in AD occurrence and progression. 
AD is a complex multi-factorial, heterogeneous disease and among environmental 
factors likely associated with it, persistent virus infections, the progressive decline of 
immune competence with advancing age and chronic psychological stress exposures  
might play a pivotal role. 
Infective agents, both bacteria and viruses, have been suggested to play a role in the 
clinical progression of AD. Impaired immune responses are associated with ageing and 
decreased defensive immunity against peripheral persistent bacterial infections and/or 
latent and reactivating viruses might expose the brain to an increased risk of 
microorganism invasion and chronic infections. These alterations may contribute to 
impair brain inflammatory responses leading to neurodegenerative processes and 
dementia. However, the role of brain innate immunity in the pathogenesis and clinical 
history of AD remains to be clarified. 
The present study focused on genes involved in antimicrobial defences, especially 
against virus infections, such as interferon regulatory factor (IRF) 7, mediator complex 
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(MED) 23, interferon (IFN)-λ3, or IL28B (interleukin 28B), and IFN-α genes. We 
attempted to evaluate the potential association of their expression in hippocampus and 
in temporal cortex AD brain samples. Since our recent findings showed that diverse 
genetic backgrounds in genes regulating antiviral responses were associated with an 
increased risk of AD, the focus of this thesis was set on single nucleotide 
polymorphisms (SNPs) located upstream of the IRF7, MED23 and IL28B genes and on 
SNPs of APOE gene, and their potential effect on the brain gene expression profiles.  
Most AD patients showed an impaired brain expression of these major antiviral 
response genes. Carriers of the APOE ε4 allele showed a significant decrease of 
MED23, IL28B and IFN-α gene expression in hippocampus area. Moreover, the 
presence of GA and AA genotype in the upstream IRF7 variant (rs6598008) was 
associated with further decreased hippocampal expression of IRF7, MED23, IL28B and 
IFN-α, which are all involved in the innate immune control of HSV-1 infection.  
The present findings suggest that brains from AD patients have defective antimicrobial 
immune defences and individual genetic makeup, such as positivity for the APOE ε4 
and IRF7 A alleles, further decreases brain immune efficiency. A decreased brain 
immune efficiency may increase the susceptibility to chronic infections during ageing, 
which in turn may activate a vicious neuroinflammatory circle leading to neuronal 
death, neurodegeneration and clinical dementia. Maintenance of efficient immune 
responses in the elderly might slowdown neurodegenerative mechanisms associated 
with the age-related cognitive decline and influence both prevalence and incidence of 
AD. 
While most cases of AD occur at late onset and older ages, increasing evidences 
support the notion that the neurodegenerative alterations precede AD clinical 
manifestation by many decades. In addition to genetics and environmental factor, 
several epidemiological reports have indicated that chronic stress and stress-related 
disorders can influence the progression of AD-related symptoms and pathologies. 
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Different studies have shown that chronic stress has a strong impact on different 
cognitive processes ranging from attention to memory and social cognition. Moreover, 
chronic stress at different stages of life, including intrauterine life, has a negative 
impact on AD pathology. The early-life environment is one of the most important factors 
affecting life-long health and prenatal stress (PNS) is an important programming factor 
in brain development and function. 
The second part of this thesis shows that in mouse model, environmental factors, such 
as PNS exposure, can be controlled and AD-related behaviour can be monitored 
throughout the disease progression. It has been investigated the long-term cognitive 
consequences of PNS in AD mice and the PNS-early neurobiological effects in wild 
type (WT) animals. As these, mice are a useful model to suggest that PNS affects the 
onset of cognitive deficit in AD mice in a sex-dependent manner. Furthermore, our 
findings highlight that the impairment of fetal neurodevelopment might influence adult 
mental health and brain ageing. Based on these results, AD is probably best 
considered in a life-course framework, with important influences beginning also at 
early-life moments.   
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Introduction 
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An Introductory Overview of Alzheimer’s Disease 
Epidemiology 
According to the World Alzheimer Report 2015 it has been estimated that the number 
of people living with dementia will almost double every 20 years, reaching 74.7 million 
in 2030 and 131.5 million in 2050 (https://www.alz.co.uk/research/world-report-2015).  
The regional estimates of dementia prevalence in people aged 60 years and over 
range from 4.6% in Central Europe to 8.7% in North Africa and the Middle East, though 
all other regional estimates fall between 5.6% and 7.6%. The regional distribution of 
new dementia cases is 4.9 million (49% of the total) in Asia, 2.5 million (25%) in 
Europe, 1.7 million (18%) in the Americas and 0.8 million (8%) in Africa. The incidence 
of dementia increases exponentially with increasing age, from 3.9 per 1000 person-
years at age 60-64, to 104.8 per 1000 person-years at age 90 and over.  
Today 47 million people live with dementia worldwide. There is a clear and urgent need 
to improve the coverage of healthcare around the world, for people living with dementia 
now and those who will be in the future. Through cost modelling, the World Alzheimer 
Report 2016 shows that these improvements are affordable and achievable, but 
governments and societies need to effect transformative change to deliver them 
(https://www.alz.co.uk/research/world-report-2016). 
Alzheimer’s disease (AD) 
AD was first identified more than 100 years ago, but 70 years passed before it was 
recognized as the most common cause of dementia1. Researchers believe that early 
detection will be key of preventing, slowing and stopping Alzheimer’s disease. 
Nowadays, there are no definitive diagnostic tests or validated biological markers for 
this disease2. Revised criteria and guidelines for diagnosing Alzheimer’s were 
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proposed and published in 20113-6. Because scientific evaluation of the proposed 
criteria is ongoing, we refers to AD as defined by the earlier criteria7.  
AD symptoms 
The AD common symptoms are:  
memory loss that disrupts daily life; challenges in planning or solving problems; 
difficulty completing familiar tasks at home, at work or at leisure; confusion with time or 
place; trouble understanding visual images and spatial relationships; new problems 
with words in speaking or writing; misplacing things and losing the ability to retrace 
steps; decreased or poor judgment; withdrawal from work or social activities; changes 
in mood and personality, including apathy and depression. 
Brain changes AD-related  
The two primary neuropathological hallmarks of AD are amyloid-beta (Aβ) plaques and 
neurofibrillary tangles (NTFs): the first ones consist of extracellular deposits of Aβ, 
which is derived from the β-amyloid precursor protein (APP), in diffuse plaques and 
plaques containing elements of degenerating neurons (neuritic plaques)2, while the 
second ones are primary composed of hyperphosphorylated tau protein accumulation 
inside neuronal cells8. Activation of microglia, astrocytes and loss of neurons and 
synapses is also widespread9. The fundamental pathogenic mechanisms underlying 
these changes are still under debate, but it is clear that environmental and genetic 
components play a pivotal role2.  
In AD, information transfer at synapses begins to fail, the number of synapses declines, 
and neurons eventually die. The accumulation of Aβ is believed to interfere with the 
neuron-to-neuron communication at synapses and to contribute to cell death. NTFs 
block the transport of nutrients and other essential molecules inside neurons and are 
also believed to contribute to cell death. The brains of people with advanced AD show 
dramatic shrinkage from cell loss and widespread debris generated by dead and dying 
neurons10. 
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AD and genetic mutations 
A small percentage of AD cases (an estimated 3% or less)11 develops as a result of 
mutations to any of three specific genes. These mutations involve the amyloid 
precursor protein (APP) gene, presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes. 
People inheriting a mutation to the APP or PSEN1 genes are guaranteed to develop 
Alzheimer’s. Those inheriting a mutation in the PSEN2 gene have a 95% chance of 
developing the disease12. Individuals with mutations in any of these three genes tend to 
develop AD symptoms before age 65, sometimes as early as age 30. On the other 
hand, the majority of individuals with sporadic AD shows a late-onset disease, 
occurring at age 65 or later. 
Known AD risk factors  
With the exception of the rare cases of Alzheimer’s caused by genetic mutations, 
experts believe that AD develops as a result of multiple factors rather than a single 
cause like other common chronic degenerative diseases. Researchers have outlined 
several factors that affect risk of developing dementia. 
 Age 
Age is the major risk factor for AD. Most patients develop AD after 65 years or at older 
ages. AD is not a normal part of ageing and age alone is not sufficient to cause the 
disease10. 
 ApolipoproteinE (APOE) ε4 allele 
ApolipoproteinE (ApoE) protein is the major cholesterol carrier in the brain. ApoE is 
involved in neuronal maintenance and repair. This protein binds several receptors on 
the cell surface, which are involved in lipid delivery and transport, glucose metabolism, 
neuronal signaling and mitochondrial function. Normally, ApoE also binds Aβ peptide 
and plays a role in its clearance13. 
There are three main polymorphisms of APOE gene, called APOE ε2, ε3 and ε4 
alleles.   
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The ε3 is the most common; the ε4 is carried by an estimated 20-30% of individuals, 
while the ε2 form is carried by an estimated 10-20% of the population12,14. Allele ε4 
positivity increases AD risk, while having the ε2 allele may decrease the disease’s risk. 
Those who inherit one copy of the ε4 allele have a 3-fold higher risk of developing AD 
than those without it, while individuals who inherit two copies of the ε4 form have an 8- 
to 12-fold increased disease’s risk15,16. In addition, subjects with the ε4 allele are more 
likely to develop AD at a younger age than those with the ε2 or ε3 alleles17. Unlike 
inheriting a genetic mutation that causes Alzheimer’s, inheriting the ε4 form of the 
APOE gene does not guarantee that an individual will develop AD.   
 Family History 
Subjects in which multiple members of the family are affected by AD are at increased 
risk for dementia, but the distribution of secondary cases is not consistent with 
Mendelian inheritance. AD is more frequent among monozygotic than dizygotic twins 
and first-degree relatives of patients with AD have approximately twice the expected 
lifetime risk of developing the disease18-21. Individuals who have a parent, brother or 
sister with AD are more likely to develop the disease than those who do not have a 
first-degree relative with Alzheimer’s16,22. However, when a disease runs in families, 
heredity along with shared environmental and lifestyle factors, play a role10.  
 Cardiovascular Disease Risk Factors 
Growing evidence suggests that the brain health is linked to the heart and blood vessel 
health. Many risk factors of cardiovascular disease are also associated with an 
increased risk of dementia. These factors include smoking23-25, obesity in midlife26,27 
and diabetes24,28-31. Growing evidence also implicates midlife hypertension27,32 and 
midlife high cholesterol33,34 as risk factors. Conversely, factors that protect the heart 
(e.g. physical activity, a diet low in saturated fats and rich in vegetables and fruits29,35-37) 
are also protective for the brain and reduce the risk of developing AD and other 
dementias.  
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 Social and Cognitive Engagement 
Additional studies suggest that social and mental activity throughout life may reduce 
the risk of AD and other dementias38-44. Remaining socially and mentally active may 
help build cognitive reserve; however, underlying mechanisms are still unknown10.  
 Traumatic Brain Injury (TBI) 
TBI is a mechanical insult to the brain caused by external forces and associated with 
inflammation and oxidative stress45. Moderate TBI increases twice the risk of 
developing AD and other dementias, and severe TBI increases 4.5 times the AD 
risk46,47. Individuals who have experienced repeated head injuries, such as boxers, 
football players and combat veterans, are at increased risk of developing dementia, 
cognitive impairment and neurodegenerative diseases48-54. Some of these 
neurodegenerative diseases, such as chronic traumatic encephalopathy, can only be 
distinguished from AD upon post-mortem brain autopsy.  
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AD and Genetics  
Early Onset Alzheimer’s Disease (EOAD) 
AD is a complex and heterogeneous neurodegenerative disease. Several genes, 
environmental factors and interactions among genes and these components may be 
involved in AD occurrence and progression55. Studies have been performed on mono- 
and di- zygotic twins to estimate the role of genetics in AD, the environmental 
influences and the disease heritability. Variation in the age of onset, neuropathological 
patterns and the disease duration may be ascribed to genetic–environmental interac-
tions56-58.  
AD can be categorized into early (age at onset <65 years) and late onset; among early 
onset families, patterns of AD inheritance have been consistent with Mendelian 
autosomal dominant inheritance. Studies from late onset familial cases suggested a 
multifactorial inheritance, involving both genetic and non-genetic factors59-61. 
Three mutations are considered main risk factors for EOAD: these mutations are on 
amyloid precursor protein (APP)62, presenilin 1 (PSEN1) and 2 (PSEN2)63-65 genes. 
Mutations in APP gene appear to cause shifts in its proteolytic cleavage toward 
amyloidogenic pathways, leading to accumulation of the Aβ42 isoform which is less 
soluble and more neurotoxic66 than the common Aβ4067 isoform. 
PSEN1 and PSEN2 share 67% homology; both genes contain twelve exons with ten 
coding exons (exons 3–12), for a ∼450 amino acids protein. PSEN1 and PSEN2 are 
transmembrane (TM) proteins with, at least, seven TM domains68. Most AD mutations 
have been detected in PSEN1 gene (approximately 30%–70% of familial EOAD), 
located on chromosome 1469. Patients with PSEN1 mutations might develop AD 
symptoms in their 40s or early 50s, with a few cases occurring in individuals in their 
late 30s and early 60s70. PSEN2, on chromosome 1, is another EOAD gene, among a 
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very small European population. The most well-known AD group with the PSEN2 
mutations is from families with the Volga German ancestry. AD patients with PSEN2 
mutations may show disease onset between 40 and 75 years71,72. 
PSEN mutations contribute to a partial loss of function in the γ-secretase complex, 
which affects APP processing and increases the brain vulnerability to Aβ toxicity73. 
However, the roles of presenilin mutations continue to be investigated74. 
Late Onset Alzheimer’s Disease (LOAD) 
LOAD comprises the majority (90–95% or more) of AD cases and there is considerable 
evidence to support a genetic component in its etiology59. Identifying genetic 
contributors to LOAD has posed great challenges; while EOAD is characterized by 
highly penetrant mutations in a few risk genes, LOAD is likely caused by multiple low 
penetrance genetic variants74. 
The first confirmed LOAD susceptibility gene was the APOE gene, located on 
chromosome 19 and coding for ApoE protein, which is involved in the transport, 
storage and metabolism of lipids74.  
To identify other genomic contributors to AD risk, a variety of approaches have been 
used: regional and genome-wide linkage studies (GWLS) in multiplex pedigrees, 
candidate gene association studies, meta-analyses of linkage and association studies, 
genome-wide association (GWA) studies and, most recently, whole genome 
sequencing (WGS) and whole exome sequencing (WES) studies74. 
The first two sets of large-scale GWA studies identified CLU (clusterin), PICALM 
(phosphatidylinositol-binding clathrin assembly protein), CR1 (complement receptor 1), 
BIN1 (bridging integrator 1), MS4A4A (membrane spanning 4-domains A4A), ABCA7 
(ATP-binding cassette sub-family A member 7), CD2AP (CD2 associated protein), 
CD33 and EPHA1 (Ephrin type-A receptor 1 precursor) as AD susceptibility loci75-78. 
17 
 
The largest GWA study to date was performed by the International Genomics of 
Alzheimer’s Project (IGAP)2. This consisted of a large, two-stage meta-analysis of the 
major GWA studies (GWAS) of individuals of European ancestry that included a total of 
74,046 subjects. In the first stage, 7,055,881 single nucleotide polymorphisms (SNPs), 
genotyped or imputed in at least 40% of AD cases and 40% of control (ctrl) samples, 
were used to perform a fixed-effects inverse variance-weighted meta-analysis on four 
previously published GWAS data sets, consisting a total of 17,008 AD cases and 
37,154 ctrl. In total, 11,632 SNPs associated with AD risk, exhibiting a p-value of <1 × 
10−3, were genotyped and tested for association in the second stage, in an independent 
set of 8,572 AD cases and 11,312 ctrl2. Additionally to the APOE locus, nineteen loci 
reached genome-wide significance, defined as p < 5 × 10−8, in the combined stage 1 
and 2 analysis [CR1, BIN1, CD2AP, EPHA1, CLU, MS4A6A (membrane spanning 4-
domains A6A), PICALM, ABCA7, HLA-DRB5/HLA-DRB1(major histocompatibility 
complex, Class II, DR beta 5/1), PTK2B (protein tyrosine kinase 2 beta), SORL1 
(sortilin related receptor 1), SLC24A4/RIN3 (Solute Carrier Family 24 - 
Sodium/Potassium/Calcium Exchanger - Member 4/Ras and Rab Interactor 3), INPP5D 
(inositol polyphosphate-5-phosphatase D), MEF2C (myocyte enhancer factor 2C), 
NME8 (NME/NM23 family member 8), ZCWPW1 (zinc finger CW-type and PWWP 
domain containing 1), CELF1 (CUGBP Elav-like family member 1), FERMT2 (fermitin 
family member 2) and CASS4 (Cas scaffolding protein family member 4)]. Out of these, 
eleven (HLA-DRB5/HLA-DRB1, PTK2B, SORL1, SLC24A4/RIN3, INPP5D, MEF2C, 
NME8, ZCWPW1, CELF1, FERMT2  and CASS4) were new association risk factors.    
The odds ratio (OR) ranged from 1.08 to 1.29; examining the genetic effect attributable 
to all the associated loci, the most strongly associated SNPs at each locus, other than 
APOE, had population-attributable fractions or preventive fractions between 1.0 and 
8.0% in the stage 2 sample. The cumulative population attributable fraction was 
89.4%2. In summary, this meta-analysis of major AD GWAS identified eleven new 
susceptibility loci. These new loci underline the significance of specific pathways 
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already shown to be enriched for association signal in AD GWAS, such as immune 
response and inflammation (HLA-DRB5/DRB1, INPP5D, MEF2C), cell migration 
(PTK2B), lipid transport and endocytosis (SORL1), and reinforced the relevance of 
some additional previously suggested pathways including APP (SORL1 and CASS4) 
and tau (CASS4 and FERMT2) pathology, hippocampal synaptic function (MEF2C and 
PTK2B), cytoskeletal function and axonal transport (CELF1, NME8, CASS4), regulation 
of gene expression and post-translational modification of proteins, microglial and 
myeloid cell function (INPPD5)2. 
Exome and genome sequencing approaches have recently yielded novel insights into 
the genetic contributors to AD. Rare loss-of-function mutations R47H and R62H in the 
chromosome 6p21.1 gene TREM2 (triggering receptor expressed on myeloid cells 2) 
have recently been found to lead to an increased AD risk of as much as 400%79-82. 
TREM2 implicates innate immunity pathways83, the regulation of phagocytic pathways 
and it has also been found to inhibit microglia cytokine production and secretion 
reducing inflammatory response84. The identification of this gene has strengthened the 
growing consensus that microglia induced neuroinflammation is a critical component of 
AD pathogenesis74. A whole-genome sequencing study examining genotypes of 1,795 
Icelanders found a coding mutation in the APP gene (A673T) that protects against AD 
and cognitive decline in the elderly without Alzheimer’s85. SORL1, which was first an 
AD candidate gene86 and then observed in the IGAP GWAS, was recently found 
through exome sequencing to carry mutations causing a form of EOAD with autosomal 
dominant inheritance87. Furthermore, exome sequencing of a Turkish family with AD 
identified a mutation (R1231C) in NOTCH3 (notch homolog 3 (Drosophila)) gene 81, 
which has previously been implicated in a subtype of vascular dementia, the CADASIL 
(Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy). 
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The next generation of AD rare variant studies is currently in development. The 
upcoming Alzheimer’s Disease Sequencing Project (ADSP; 
https://www.niagads.org/adsp/content/home) is a joint project by the National Institute 
on Aging and National Human Genome Research Institute to identify novel risk and 
protective variants for AD in nearly 600 whole genomes from 110 multiplex pedigrees 
heavily burdened with AD, and approximately 10,500 whole exomes on unrelated AD 
cases and non-demented ctrl. This kind of studies promise to characterize the yet 
unknown heritable component in Alzheimer’s susceptibility, that has been defined as 
the “dark matter” of the AD genetics74.  
In previous works of Licastro’s team88,89, genetic data from four AD GWAS75-77,90 were 
discussed and it was suggested that the above genes75-77,90 might be linked to herpes 
viral infections. In particular, it has been argued that the association of these genes 
with AD is suggestive of a pivotal role of environmental factors in the pathogenesis of 
the disease and, according to a non conventional interpretation of AD etiology, virus 
infection88,89 is one AD etiologic component. In other words, the genetic signature 
revealed by GWA studies discloses a network of genes that might influence the ability 
of the central nervous system (CNS) to cope with and fight against the invasion by 
virus of the herpes family88,89.  
In spite of the great number of AD patients and ctrl subjects from GWA studies, each 
SNP alone showed a low OR for the disease. Potential interactions between several 
SNPs in different genes could be more illuminating to understand the etiopathogenesis 
of this multi-factorial neurodegenerative disease, since the aforementioned genes are 
involved in different aspects of AD pathogenesis and clinical history. On the other 
hand, environmental AD risk factors, as microbial infections, might trigger several of 
these genes, depending on the presence and/or the absence of the above interacting 
SNPs, and influence individual immune responses. Therefore, it has been suggested 
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that virus belonging to the herpes family might be one of the missing link between 
these genetic variants and the individual AD clinical history.    
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AD and Inflammation 
The modulation of the neurodegenerative disease course by specific immune 
molecules in preclinical experimental approaches and the up-regulation of inflammatory 
genes in arrays on tissues derived from patients with neurodegenerative diseases are 
indicative of a relationship between inflammation and these diseases and implicate 
early immune actions in their pathogenesis91-95. 
Classically AD has been viewed as a neurodegenerative disease of the elderly, 
characterized by the extracellular deposition of misfolded Aβ peptide and by 
intraneuronal accumulation of NTFs. Thereafter, neuroinflammation has emerged as an 
important component of AD pathology8,93. Experimental, genetic and epidemiological 
data indicate a crucial role for activation of the innate immune system as a disease-
promoting factor93. The inflammatory reaction observed in AD is primarily driven by 
CNS-resident immune cells, included microglia, perivascular myeloid cells and other 
elements such as astrocytes, and reflects the tissue reaction to pathological events that 
occur during the disease8. 
Microglia cells are the CNS macrophages that continuously scrutinize their 
environment for damage. Microglia colonize the cephalic mesenchyme during 
embryogenesis and actively shape the developing neuronal network by immune-
mediated mechanisms. During CNS maturation, microglia drastically change 
phenotype and function. Adult microglia contribute to brain homeostasis, but also the 
establishment and resolution of inflammatory conditions96. Under pathological 
conditions, CNS environment changes and microglia respond by activation and 
potential redirection of their phagocytic activity from synaptic pruning to clearing 
dangerous factors96-98. Long-lasting chronic inflammation has been proposed to drive 
microglial physiological functions off balance96. Microglia are equipped to sense the so-
called danger signals (Damage Associated Molecular Pattern, DAMP) and changes in 
22 
 
neuronal health by adopting a set of different morphological and functional attributes99. 
Microglia cells are the most intimately associated with tissue changes that are 
observed in AD8. In both in vitro and in vivo experiments, microglia exhibit receptor-
dependent interactions100-103 with various forms of Aβ (monomers, oligomers, 
protofibrils, fibrils and plaques) as well as non-receptor mediated interactions, 
particularly with Aβ oligomers104. Aβ species can stimulate changes in microglial 
functions through signalling receptors105, that induce production of inflammatory 
mediators by other cells, such as astrocytes106. Aβ peptides also affect post-phagocytic 
processes within microglia, including lysosomal injury, which acidifies the cytosol and 
contributes to activating the NLRP3 (NACHT, LRR and PYD domains-containing 
protein 3) inflammasome107. Receptor-mediated interactions between microglia and Aβ 
monomers induce a “primed state”, characterized by heightened responses to 
subsequent DAMP or cytokine stimuli8. Some microglia function, such as motility and 
phagocytic activity, are impaired in APP/PS1 AD mouse model108, by oligomeric Aβ109. 
This functionally compromised state affects the microglial cells during 
neurodegenerative processes and microglia become “dystrophic”; such phenotype 
consists of microglial burn out8. It is more appropriate to view the transformed microglia 
as being indicative of a loss of tissue homeostasis. Because microglia carry out critical 
physiological tasks in the healthy brain110,111, the phenotypically transformed microglia 
may contribute to CNS tissue pathology8. 
According to this view, rare structural variants of genes encoding the immune receptors 
TREM280,82,112,113, CD3377,114 and CR1115, all of which are expressed on microglia, have 
been found associated with AD risk. TREM2 is involved in regulating microglial 
phagocytosis116,117 and has also a relevant impact in vivo in different AD mouse 
models, by promoting the survival of activated microglia and their peripherally derived 
myeloid counterparts118,119 and by recruiting these cells around Aβ plaques118-120 and 
dying neuronal cells118. CD33 variants have also been associated with an increased 
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risk of developing AD77,114. All these findings support the concept of impaired microglial 
function in AD. 
During ageing, number and density of microglia increase significantly and the regularity 
of the microglia distribution also appears to deteriorate121. Aged microglia undergo 
changes in their ramified morphology and decreased dynamic motility121. Multiple lines 
of evidence have indicated that microglia in the aged CNS show increased basal states 
of activation and increased expression levels of inflammatory cytochine121. It has also 
been suggested that the ageing of microglia might be partially driven by a cumulative 
history of environmental influences such as systemic infections over a life-time121. 
Therefore, microglial cells in AD brains might be primed by infectious agents 
challenging the CNS and/or by temporary permeabilization of selected districts of blood 
brain barrier (BBB) induced by the persistence of peripheral subclinical inflammatory 
responses122.  
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AD and Environmental Risk Factors 
Health and disease in the brain are influenced by multiple factors. These factors are 
genetic or environmental. In sporadic AD, different genetic and environmental factors 
might interact.  
Over the past decade, epidemiological surveys have identified several risk factors for 
AD, including ageing, systemic infections, inflammation, midlife obesity, brain trauma, 
chronic periodontitis, toxic chemical exposures, reduced physical activity and chronic 
psychological stress exposures93,123-129. Interestingly, most of these risk factors involve 
the activation of innate immunity. Experimental evidence suggests that systemic 
inflammation exerts detrimental effects on brain functions93. Post-mortem analysis of 
brains from patients who had suffered septicemia has shown a distinct increase in 
microglial activation130. Those data are complemented by findings showing persistent 
cognitive alterations, hippocampal atrophy and electroencephalograph changes in 
patients who survive sepsis131. Brain trauma is also characterized by a strong 
neuroinflammatory reaction45,93. Moreover, trauma-induced activation of microglia has 
been shown to increase the Aβ deposition in an AD mouse model132 and underlying 
mechanisms might include cytokine release and impaired microglial clearance93.  
Infections 
An infection/immune component might play a role in AD etiopathogenesis. There are 
several studies, mainly on humans, implicating specific microbes in the AD etiology, 
notably herpes simplex virus type 1 (HSV-1), Chlamydia pneumonia, Helicobacter 
pylori and several types of spirochetes133-137. The presence of fungal infection in the 
brain of AD patients has also been observed138,139. On the other hand, plasma 
concentrations of TNF and antibodies to periodontal bacteria were found to be higher in 
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AD patients compared to non-demented ctrl subjects and were independently 
associated with AD140,141.  
Virus of Herpes Family and Dementia 
Herpes simplex virus type 1 (HSV-1) and AD 
The first observations of HSV-1 in AD brain were reported in 1991142. The increasing 
number of these studies warrants re-evaluation of the infection and AD concept 143. As 
previously described88,89, Licastro’s group discussed genetic data from four GWAS on 
AD75-77,90. From these investigations a set of SNPs associated with AD emerged and it 
has been hypothesised that the concomitant presence of these SNPs might result in a 
genetic signature predisposing to AD, via complex and diverse mechanisms each 
contributing to an increased individual susceptibility to herpes virus infection88,89.   
An AD viral etiology, especially involving herpes virus, has been already proposed and 
most works have shown an association between HSV-1 and AD144-148.  
HSV-1 is a ubiquitous virus that infects more than 80% of over 65-year-old individuals 
worldwide149. HSV-1 is a neurotropic double-stranded DNA virus that primarily infects 
epithelial cells of oral and nasal mucosa. Here, the virus undergoes lytic replication. 
The newly produced viral particles may enter sensory neurons and, by axonal 
transport, reach the trigeminal ganglion where usually establish a latent infection. The 
virus undergoes periodic reactivation cycles, in which the newly formed viral particles 
are transported back to the site of primary infection through the sensory neurons, 
causing the typical clinical lesions, commonly referred to as cold sores. However, the 
bipolar trigeminal ganglion neurons also project to the trigeminal nuclei located in the 
brainstem. From here, neurons project to the thalamus to finally reach the sensory 
cortex. This represents the path through which the reactivated virus may reach the 
CNS, where it may cause acute neurological disorders like encephalitis (Herpes 
Simplex Encephalitis, HSE), mild and clinically asymptomatic infection or establish life-
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long latent infection150,151. Recent findings showed a significant association of HSV-1 
infection with AD risk150. A reactivation of HSV-1 infection, assessed by increased 
serum levels of specific anti-HSV-1 antibodies, was found associated with an increased 
AD risk in a longitudinal study on 3,432 Swedish elderly150. Another study from Italy 
reported that elevated serum HSV-1 antibody titers correlated with reduced cortical 
grey matter volume as assessed by MRI152.   
Itzhaky and colleagues in their recent editorial143 discussed relevant evidences in 
favour of an HSV-1 infectious component in AD etiopathogenesis. HSE causes 
damage in localized CNS regions related to the limbic system153, the same regions as 
those affected in AD143. In brain of AD patients, the presence of HSV-1 DNA 
specifically colocalize with AD pathology148. In mice and in cell cultures, Aβ and NTFs 
were observed after HSV-1 infection143 and a direct interaction between APP and HSV-
1 has been reported154. Antiviral drugs, including acyclovir, in vitro block HSV-1-
induced Aβ and tau pathology155. Olfactory dysfunction is an early symptom of AD and 
the olfactory nerve, the initial site from where characteristic AD pathology subsequently 
spreads through the brain, is another potential portal of entry of HSV143. Further, 
brainstem areas that harbour latent HSV directly project the brain regions involved in 
AD pathology: brainstem virus reactivation would thus disrupt same tissues as those 
affected in AD143. 
Moreover, others herpes viruses share the ability to become latent in the infected host 
and eventually latently infect neurons149, but investigations focused on herpes viruses 
such as human cytomegalovirus (CMV), Epstein-Barr virus (EBV) or human herpes 
virus 6 (HHV-6) in AD are scarce.  
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Cytomegalovirus (CMV) and AD 
CMV is ubiquitously distributed in human population and the most frequent cause of 
brain infection in immune compromised patients or in infants with congenital virus 
transmission156,157. Postnatal acute peripheral CMV infection is usually asymptomatic, 
however, the virus, once established, remains latent in blood monocytes158,159. Several 
studies described CMV as a potential risk factor for AD122. For instance, an increased 
rate of cognitive decline over a four year period in subjects with elevated CMV antibody 
levels has been reported160. However, results regarding this topic have been 
conflicting122. Lin and colleagues, analysing brain frontal and temporal cortex samples, 
found that both AD patients and elderly healthy subjects were positive for CMV, with no 
statistically significant difference between the two groups161. On the other hand, brain 
positivity for CMV was found in a greater proportion of patients with vascular dementia 
than normal elderly and these findings suggested a virus role in the disease162. CMV 
was also present in cerebrospinal fluid (CSF) of subjects with encephalitis or meningitis 
or other neurological condition163. A recent investigation reported increased CMV 
antibody levels in the elderly who developed clinical AD during a five-year follow-up164. 
Furthermore, findings from a longitudinal follow-up of 849 participants in the USA 
showed that CMV infection doubled the risk of developing AD165, even if some 
criticisms to this type of data have been presented166. 
Epstein-Barr virus (EBV) and AD 
EBV infects more than 95% of human beings within the first years of life. The virus is 
the etiological agent of acute infectious mononucleosis in a minority of immune 
competent subjects, while the majority develops a life-long asymptomatic infection. 
EBV remains latent in B lymphocytes149,167,168. Data describing an association between 
EBV and AD are very limited; only two papers from 1992 described a possible 
correlation between EBV and AD, however, with discordant results169,170. Recently, our 
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findings showed a positive association of peripheral blood positivity for EBV genome 
and AD, and elevated levels of EBV specific antibodies positively associated with an 
increased risk of developing AD164. 
Human herpes virus (HHV)-6 and AD 
HHV-6 is a neurotropic virus, present in two different variants171, with a very high sero-
prevalence, involving almost 100% of population by the age 3172. HHV-6 establishes 
latency in the brain and may reactivate under conditions of immunosuppression171. It 
has been associated with multiple neurological diseases including seizures, 
encephalitis, mesial temporal lobe epilepsy and multiple sclerosis173. HHV-6 has been 
found in a higher proportion of AD than age-matched ctrl brains161. Recently, Agostini 
and colleagues showed no difference in serum HHV-6 IgG antibody titers and the 
avidity index between AD patients, MCI and ctrl individuals174. Another study showed 
an higher value of HHV-6 levels in ctrl brains175. On the other hand, our findings 
showed an elevated positivity for HHV-6 genome in the brains and in peripheral blood 
cells of AD patients and an increased sero-positivity associated with increased risk of 
developing AD164. 
In summary, research in epidemiology, neuropathology, molecular biology and 
genetics, regarding the hypothesis that pathogens interact with susceptibility genes and 
contribute to sporadic AD, is conspicuous but underestimate135. Sporadic AD is a 
complex multi-factorial neurodegenerative disease with evidence indicating coexisting 
multi-pathogen and inflammatory etiologies135. Pathogens like those aforementioned 
are able to evade destruction by the host immune system, leading to persistent 
infection. Viral DNA, but also viral RNA and/or bacterial ligands, increase the 
expression of proinflammatory molecules and activate the innate and adaptive immune 
systems. Chronic brain infections like those caused by HSV-1, Chlamydophila 
pneumonia and spirochetes result in complex processes inducing uncontrolled 
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neuroinflammation and neurodegeneration. Infections such as those caused by CMV, 
Helicobacter pylory and periodontal pathogens induce production of systemic 
proinflammatory cytokines that may cross the BBB to promote neurodegeneration. 
Moreover, pathogen-induced inflammation and CNS accumulation of Aβ damage the 
BBB, which in turn contributes to the pathophysiology of AD135. 
Antiviral Defence and The New Interferon Lambda (IFN-λ) Family  
Interferon lambda (IFN-λ), also called type III IFN or IFNL, represents the most recently 
described family of IFNs and plays pivotal roles in host-pathogen interactions176. 
The IFN-λ family comprises four homologous members: IFNL1 (Interleukin IL29), 
IFNL2 (IL28A), IFNL3 (IL28B) and the more recently described IFNL4176. They belong 
to a cytokine family that shares functional similarities with the family of type I IFNs (IFN-
α/β)177. Genes encoding type I IFNs characteristically lack introns (with the exception of 
IFNK) and are located in a single locus on human chromosome 9 and mouse 
chromosome 4. Genes encoding IFN-λ are located on human chromosome 19 and 
mouse chromosome 7 and share the 5-exon gene structure characteristic of IL-10 
(Interleukin 10) cytokine family members178.  
IFN-λ biology partially differs from IFN- α/β biology. First, the effects of IFN-λ are most 
evident on epithelial cells, suggesting that it contributes to the specialized immune 
mechanisms that protect epithelial surfaces, which are constantly exposed to 
commensal and pathogenic microbes179-181. Second, because of the more focused 
nature of its signalling effects, IFN-λ might share the therapeutic benefits of IFN-α/β 
without side effects that have limited the clinical use of IFN-α/β180,182-184. Third, GWA 
studies have reported several IFN-λ SNPs that are linked to clearance of hepatitis C 
virus (HCV) infection and possibly improved outcomes with other viral infections, 
including hepatitis B virus (HBV), CMV and HSV-1176,185-187. Although the mechanisms 
by which these SNPs affect IFN-λ production and activity remain unclear, these 
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associations reinforce the notion that IFN-λ contributes to the control of chronic viral 
infections in humans177.  
Stimuli inducing expression of IFN-λ encoding genes are similar to those inducing 
expression of IFN-α/β genes. As would be expected from an antiviral cytokine, IFN-λ 
can be induced by a wide range of viruses in different cell types179,188,189. IFN-λ is 
expressed in a variety of primary human cell types of the hematopoietic lineage, that 
also produce type I IFNs in abundance190. Among non hematopoietic cells, epithelial 
cells are potent producers of IFN-λ190. The induction of IFNs is mediated by pattern-
recognition receptors (PRRs) that recognize the invading virus177 and the set of PRRs 
and transcription factors expressed by a cell contributes to its specific capabilities and 
magnitude of the IFN release following infection191. Early studies have shown that IFN-
λ genes have binding sites for the transcription factors NF-κB, IRF3, IRF7 and AP-1 in 
their promoter regions192-194 and can therefore be coexpressed with type I IFNs. 
Additionally, it was suggested that IFN-λ2 and –λ3 are more dependent on IRF7 and 
seem to have delayed expression kinetics190. Human hepatocytes infected with HCV or 
treated with polyinosinic-polycytidylic acid (polyI:C), released IFN-λ2 and –λ3 by 
induction of IRF3 and IRF7, whereas the induction of IFN-λ1 was also dependent on 
NF-κB195. Finally, another group has identified Med23, a subunit of the mediator 
complex, as a direct interaction partner for IRF7, showing how Med23 and IRF7 
synergistically increase IFN-λ transcription and inhibit HSV-1 replication196.    
The proximal signaling events and downstream transcriptional responses are similar 
between IFN-α/β and IFN-λ, even though these cytokines and their receptors are 
structurally and genetically distinct. The IFN-λ structure resembles that of members of 
IL-10 family, although the primary amino acid sequence of IFN-λ is more similar to that 
of IFN-α/β177. Whereas all type I IFNs signal through a shared heterodimeric receptor, 
IFNAR (IFNAR1 and IFNAR2), IFN-λs bind to IFNLR, a unique heterodimeric receptor. 
IFNLR is formed by one subunit shared with other IL-10 family cytokines (IL10Rb) and 
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one subunit specific for IFN-λ (IFNLR1, also called IL28Ra). Although IFNAR and 
IL10Rb are expressed broadly on many cell types and tissues, IFNLR1 is expressed 
mainly on epithelial cells181,197. Consistent with this pattern, the antiviral effects of IFN-λ 
are more evident against pathogens targeting epithelial tissues177. 
Although epithelial cells produce IFN-λ, myeloid-lineage cells are major sources of the 
cytokine in response to double-stranded RNA (polyI:C) or viral infections198. In the 
small intestine, epithelial and immune cells both respond to polyI:C stimulation, 
suggesting that multiple cell types produce IFN-λ cooperatively181. Whereas 
plasmacytoid dendritic cells (DCs) produce nearly all IFNs, including IFN-λ, monocytes 
and myeloid DCs more selectively express IFN-β, IFN-λ1 and IFN-λ2191.  
 A recent study on West Nile virus (WNV) infection demonstrated an antiviral effect of 
IFN-λ in correspondence to the BBB199. Ifnlr1_/_ mice exhibited increased BBB 
permeability after WNV infection and sustained higher viral titers in CNS tissues. 
Although endothelial cells, including those composing the BBB, did not express high 
levels of IFNLR, administration of exogenous IFN-λ tightened the BBB, restricted viral 
neuroinvasion, reduced viral titers in the CNS and protected mice from lethal viral 
infection. These observations are consistent with those of a study demonstrating that 
IFN-α/β can also exert a tightening effect on the BBB200. Ultimately, our recent findings 
showed that SNPs in genes regulating antiviral responses such as IFN-λ, IRF7 and 
MED23 are differently distributed in AD and influence a differential positivity to EBV 
and HHV-6 DNA in the elderly 201. Moreover, risk alleles were increased in elderly 
progressing to AD 201. These findings support the hypothesis that individual genetic 
background may play a role in the progression of cognitive impairment by influencing 
the efficiency of immune responses to persistent viruses. 
  
32 
 
Prenatal Stress (PNS) 
Stress is ubiquitous in our daily lives and has a strong impact on different cognitive 
processes ranging from attention to memory and social cognition202-204.   
Epidemiological data have indicated that environmental factors, such as chronic stress 
exposures and stress-related disorders, can impact on the progression of AD-related 
symptoms and pathologies205-207. Recently, a meta-analysis of 20 studies found that a 
history of depression approximately doubled the risk for the later development of AD206. 
Similarly, recent prospective cohort studies found that the tendency to experience 
psychological distress was associated with a 10-fold increased risk of episodic memory 
decline128 and a 2.7-fold increased risk of developing AD127.  
One key mechanism linking stress with increased AD risk and cognitive decline is the 
hypothalamic pituitary adrenal (HPA) axis, also known as stress-response axis. Stress 
triggers the activation of the HPA axis, culminating in the production of glucocorticoids 
(GCs) by the adrenal gland. Receptors for these steroids are expressed throughout the 
brain and they can act as transcription factors regulating gene expression208. Thus, 
glucocorticoids potentially have long-lasting effects on the functioning of the brain 
regions that regulate their release208 such as the limbic system, hypothalamus and 
cortex209.  
Every day, parents observe the growing behavioural repertoires of their infants and 
young children, and the corresponding changes in cognitive and emotional functions. 
These changes are thought to relate to normal brain development, particularly the 
development of the hippocampus, the amygdala, the frontal lobes and of the complex 
circuitry that connects these brain regions. At the other end of the age spectrum, we 
observe changes in cognition in our grandparents and parents during ageing, which are 
related to both normal and pathological brain processes ageing-associated. Studies in 
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animals and humans have shown that during both perinatal life and old age the brain is 
particularly sensitive to stress, probably because CNS undergoes important changes 
during these life periods208. Furthermore, research now relates exposure to early-life 
stress with increased reactivity to stress and cognitive deficits in adulthood and elderly, 
indicating that the effects of stress at different periods of life interact208. Many studies 
have shown that stressful events during the intrauterine life exert long-lasting effects on 
the brain by affecting the nervous, neuroendocrine and immune systems209-211. 
Moreover, studies in humans and rodents, revealed a clear impact of early-life stress 
on the development of neuropsychiatric disorders such as autism, mood disorders and 
schizophrenia208.   
Investigating early-life stress exposure-related effects on AD progression is 
challenging, particularly for the epidemiological setting, because of the large and 
extremely variable time span between early stress exposures and clinical manifestation 
of AD. In addition, the number, type, and frequency of the exposures cannot be 
controlled, making it difficult understanding the contribution of each individual exposure 
to the disease. Indeed, by using animal models, environmental exposure can be strictly 
controlled and AD-related behaviour and neuropathology can be monitored throughout 
the disease progression212. However, the effects of prenatal stress (PNS) on the 
development of AD have been poorly investigated in animal models, even though it is 
well documented that prenatal maternal stress exposure can strongly contribute to an 
individual’s predisposition for developing adult psychopathology208,213,214. 
Interestingly, two animal studies showed a causal link between disturbances of 
embryonic development by maternal stress and the risk of AD-like 
neuropathology214,215. In the first one, Krstic and colleagues provided the first evidence 
that a maternal immune challenge during the late-gestational time window predisposes 
wild type (WT) mouse offspring to develop AD-like neuropathology during ageing215. 
Animals prenatally stressed by maternal immune challenge displayed chronic elevation 
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of inflammatory cytokines, an increase in the levels of hippocampal APP and its 
proteolytic fragments, altered tau phosphorylation, mis-sorting to somatodendritic 
compartments and significant impairments in working memory in old age. If the 
prenatal maternal infection is followed by a second immune challenge in adulthood, the 
phenotype is further exacerbated and mimics AD-like neuropathologic changes215. 
Furthermore, Sierksma and colleagues explored whether the combination of genetic 
variations and exposure to stress during prenatal life could affect behavioural and 
neuropathological phenotype of APPswe/PS1dE9 (AD mouse model) offspring214. They 
studied the effects of PNS in both male and female APPswe/PS1dE offspring in terms 
of cognition, affect and AD-related neuropathology. They demonstrated that PNS 
exerts a sex-dependent effect: PNS induced spatial memory deficits and a blunted 
HPA axis response in male offspring. PNS improved spatial memory performance, 
increased depressive-like behaviour and decreased hippocampal plaque load in 
females214.  
PNS exposure is likely to alter AD development by modifying the effects of an 
individual’s genetic predisposition216,217 likely through epigenetic regulation of gene 
expression218,219. Interestingly, the prenatal period is characterized by high levels of 
epigenetic programming and imprinting, enabling perturbations to exert long-lasting 
effects. In this light, it was suggested that the origin of most diseases that are 
expressed later in life, such as AD, may find their origin in altered epigenetic regulation 
in response to environmental cues arising during critical periods of development, such 
as the pre- and neonatal period220-222.  
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Antiviral innate immune response in the brain of 
Alzheimer’s disease (AD) patients 
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Human Brain Sampling 
Post-mortem brain tissues of AD patients and age-matched non-demented controls 
(ctrl) were obtained from the Netherlands Brain Bank (NBB; Amsterdam, The 
Netherlands), which abides all rules and regulations laid down in the ethical Code of 
Conduct of BrainNet Europe. Patients or their next of kin gave written informed consent 
to NBB for brain autopsy and use of tissue and clinical information for research 
purposes. This study was approved by NBB scientific committee and all conditions for 
the transfer and the use of the material are laid down in the Material Transfer 
Agreement (MTA). Staging of AD pathology was evaluated according to Braak and 
Braak criteria for neurofibrillary tangles (NFTs)223,224 and Thal criteria for amyloid 
deposition223,224, and based on neuropathological evaluation of formalin-fixed, paraffin-
embedded tissues from eighteen brain areas.  
AD cases were selected based on clinical and neuropathological reports, and 
availability of tissues stored in liquid nitrogen. 20 μm thick frozen tissue slices of the 
hippocampus and temporal cortex were cut at -20°C and stored at -80°C for the 
following molecular analyses. The final selection was based on the availability of DNA 
and RNA samples of good quantity and quality. 
Twenty-nine AD hippocampus brain samples, nineteen AD temporal cortex brain 
samples, and six hippocampus, four temporal cortex samples from ctrl cases were 
included in this study.    
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Table 1. Post-mortem AD brain samples and general data summary 
ID  Age 
(years) 
Gender 
Clinical 
diagnosis 
DD PMI 
(h) 
BW 
(gr) 
Cause of death 
Brain 
Area 
05-082 78 F MID 7 4.35 1043 Pneumonia, cachexia, decubitus Hip; Temp 
04-087 78 F AD 10 4.50 1105 Gastrointestinal bleeding Hip; Temp 
06-037 81 M AD 5 4.50 1253 
Probable CVA and sepsis with 
unknown underlaying disease Hip 
03-020 95 F 
MID likely 
mixed with AD 7 3.40 1032 Aspiration pneumonia Hip 
05-002 86 M MID 6 3.40 1206 
Metabolic disturbances, 
dehydration, metastasized prostate 
carcinoma 
Hip; Temp 
05-008 84 F MID NA 3.40 1109 Dehydration, cachexia Hip; Temp 
06-214 92 F VD 3 3.40 1115 Bleeding gastric ulcer Hip 
07-094 73 F AD 12 3.40 1082 Sepsis, cachexia Hip 
04-062 67 F presenile AD 15 3.40. 945 Cachexia Hip; Temp 
05-039 93 M AD 1 3.40 1210 NA Hip 
05-095 93 M MID 9 3.40 1220 
Cardiac decompensation caused by 
pneumonia Hip 
02-307 69 M NA NA 3.40 1241 Dehydration, cachexia Hip 
04-111 89 F AD 11 3.40 1211 NA Hip 
05-090 84 F AD NA 3.40 1098 Dehydration Hip 
06-248 91 F AD 5 3.40 1101 
Dehydration, cachexia and probable 
CVA Hip; Temp 
05-040 93 F AD 4 2.30 1045 Cachexia Hip; Temp 
04-185 86 F AD 10 5.05 998 
Uncontrolled anti-coagulation in 
combination with general 
deterioration after hip prosthesis Hip 
04-166 94 F VD after CVA 6 5.05 1170 
Cachexia and dehydration, 
decubitus Hip 
03-051 75 F AD 9 6.00 1129 Dehydration Hip 
05-050 89 F VD 19 4.30 1185 Pneumonia Hip; Temp 
09-198 74 M AD 2 5.35 1380 
Anaemia, hepatic dysfunction, 
extensive lymphoadenopathy by M. 
Kimura Hip 
06-132 75 F AD 6 15.0 1230 Cardiac arrest Hip 
09-307 94 F AD 6 8.05 1053 Cachexia Hip 
09-285 90 F AD 6 5.40 1100 
Cerebro vascular accident, 
advanced AD Hip 
09-019 88 F NA 1 6.45 1170 Natural death Hip 
09-271 66 F AD 6 6.30 1190 
Acute heart failure by advanced 
dementia syndrome Hip 
07-036 82 F VD 6 5.55 1225 
Cardiac arrest with dehydration after 
MI Hip 
07-053 99 F AD 5 3.30 1150 Airway infection Hip 
07-116 60 M 
AD likely of 
Lewy Body 
type 3 6.15 1241 
Cachexia and dehydration by 
dementia syndrome Hip; Temp 
09-010 81 F AD 2 6.10 1295 
Cachexia and dehydration by 
dementia syndrome Temp 
08-289 57 M presenile AD 6 3.50 1055 Aspiration pneumonia  Temp 
10-050 69 M VD, CI 3 7.10 1173 Aspiration pneumonia  Temp 
10-036 86 M AD 6 6.15 1331 
Possible cardiac arrest after 
gastroenteritis by AD Temp 
10-002 92 F AD 5 3.25 1105 Probable CVA  Temp 
01-032 88 F AD 12 12.15 935 Cachexia and decubitus Temp 
01-145 85 F MID 5 4.45 1310 Shock due to acute abdomen Temp 
39 
 
Table 1. Post-mortem AD brain samples and general data summary 
 
ID  Age 
(years) 
Gender 
Clinical 
diagnosis 
DD PMI 
(h) 
BW 
(gr) Cause of death 
Brain 
Area 
02-314 94 F NA NA 5.00 1410 Double sided pneumonia Temp 
10-030 80 M NA NA 4.00 1328 Unknown Temp 
01-111 85 M 
AD likely 
combined with 
MID 
5 4.25 1458 
Sudden death (suspected heart-
failure 
Temp 
Abbreviations: DD, Disease Duration; PMI, Post-mortem Interval; BW, Brain Weight; F, female; M, male; 
MID, Multi-Infarct Dementia; AD, Alzheimer’s Disease; VD, Vascular Dementia; CI, Cognitive Impairment; 
CVA, Cerebrovascular Accident; MI, Myocardial Infarction; Hip, hippocampus; Temp, temporal cortex; NA, 
Not Applicable. 
  
40 
 
Table 2. Post-mortem AD brain samples and neuropathological details 
ID  
Pathological 
Diagnosis 
Grade 
(Braak, 
NTFs) 
Grade 
(Thal, 
Aβ) 
05-082 AD 5 C 
04-087 AD 5 C 
06-037 AD 4 C 
03-020 AD; meningioma 4 C 
05-002 AD; cerebral contusion  3 A/B 
05-008 AD 5 C 
06-214 AD; infarction 4 C 
07-094 AD 5 C 
04-062 AD 6 C 
05-039 AD 5 C 
05-095 AD; caa; arg 4 C 
02-307 AD 6 C 
04-111 AD 5 C 
05-090 AD; infarction 5 C 
06-248 AD 4 C 
05-040 AD 4 C 
04-185 AD 4 C 
04-166 AD; infarction 4 C 
03-051 AD; caa  5 C 
05-050 AD 6 C 
09-198 AD 6 C 
06-132 AD 5 C 
09-307 AD 4 C 
09-285 AD; infarction 6 C 
09-019 AD 5 C 
09-271 AD 5 C 
07-036 AD 4 C 
07-053 AD 4 C 
07-116 AD 6 C 
09-010 AD 5 C 
08-289 AD 6 C 
10-050 AD; infarction 5 B 
10-036 AD 5 C 
10-002 AD; ischaemia 5 C 
01-032 AD 4 C 
01-145 AD 5 C 
02-314 AD 4 C 
10-030 AD 4 C 
01-111 AD 5 B/C 
    
Abbreviations: caa, congophilic angiopathy; arg, argyriphilic grain disease. 
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Genomic DNA Isolation 
20 μm thick frozen tissue slices of hippocampus and temporal cortex were cut at −20 
°C and collected in RNAse free eppendorf vials. Genomic DNA was obtained from 
frozen samples and purified according to the Phenol:Chloroform:Isoamyl Alcohol 
(25:24:1) extraction’s protocol (Sigma-Aldrich, St. Louis, MO) after overnight incubation 
with proteinase K 10 mg/ml (Roche, Basel, SW) and ATL buffer (Qiagen, Hilde, DE). 
Absorbance measurements were made on NanoDrop 1000 (Thermo Scientific, 
Wilmington, DE) and the ratio of absorbance at 260 nm and 280 nm was used to 
assess the purity of DNA samples, further stored at -80°C. 
RNA Isolation 
20 μm thick frozen tissue slices of hippocampus and temporal cortex were cut at −20 
°C, and collected in RNAse free eppendorf vials, whereafter RNA-Bee (AMSBIO, 
Cambridge, MA) was added. 
Totally RNA extraction from frozen hemi-brain hippocampus or temporal cortex 
samples was performed using RNA-Bee kit (AMSBIO, Cambridge, MA) according to 
manufacturer’s instructions. Total RNA was purified according to phenol-clorophorm 
standard extraction after overnight incubation with proteinase K. Absorbance 
measurements were made on NanoDrop 1000 (Thermo Scientific, Wilmington, DE) and 
the ratio of absorbance at 260 nm and 280 nm was used to assess the purity of RNA 
samples, further stored at -80°C. 
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Quantitative Reverse - Transcription Polymerase Chain 
Reaction  
Total RNA (50 ng) was retro-transcribed using the iScript™ cDNA Synthesis Kit (Bio-
Rad, Hercules, CA) following the manufacturer’s instructions. PrimerPCR™ assay for 
real-time PCR gene expression analysis was performed using SsoAdvanced™ 
Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA) according to the 
manufacturer's instructions. Bio-Rad pre-validated primer pairs for target genes IRF7 
(qHsaCED0007783), MED23 (qHsaCID0007348), IL28B (qHsaCED0038284), IFN-α 
(qHsaCED0037471) and for two reference genes were used. CYC1 
(qHsaCED0047348) and EIF4A2 (qHsaCED0023870) were selected as reference 
genes for normalization as suggested by Penna and colleagues225.   
Quantitative Real-Time pcr assay (qRT-pcr) for gene expression analysis was realized 
in a Bio-Rad CFX96™ instrument and all reactions were run in triplicate in 96-well 
optical plates. 
Data from qRT-pcr experiments were analyzed by relative quantification with Bio-Rad 
CFX Manager software. Using the 2−ΔΔCt method226, the gene expression data are 
presented as the fold change in gene expression normalized to the two reference 
genes (CYC1 and EIF4A2) and relative to the non-demented control (ctrl) samples.   
SNPs detection 
TaqMan® SNP Genotyping Assay (Applied Biosystems, Foster City, CA) was used to 
genotype AD patients according to the manufacturer’s instructions. It included an 
unlabelled PCR primer pair to detect specific target SNP and two different Taqman 
probes that distinguished two alleles of the SNP: one probe labelled with VIC® dye and 
the other one labelled with 6-FAM® dye. Allelic discrimination was based on the 
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generated signal from each probe at the end of the real-time PCR (RT-pcr) using 
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA). 
APOE genotyping for the ε allele (rs429358 and rs7412) from AD hippocampus and 
temporal cortex DNA samples was assessed by RT-pcr using Taqman® probes 
according to the manufacturer’s instructions (table 3). The upstream variant of IRF7 
(rs6598008 A/G), MED23 (rs3756784 T/G), IL28B (rs12979860 C/T) genes were also 
analyzed by RT-pcr using Taqman® probes according to the same manufacturer’s 
instructions. Thereafter, qRT-pcr data showing relative expression (2-∆Ct values227) to 
the reference genes (CYC1 and EIF4A2) of AD patients were grouped in APOE ε4 
alelle carrier/non carrier and according to SNP genotypes of IRF7 (rs6598008), MED23 
(rs3756784) and IL28B (rs12979860). 
 
Table 3. The APOE genetic variants 
APOE genotyping for ε allele 
APOE genotype rs429358 rs7412 
ε2/ε2 T/T T/T 
ε2/ε3 T/T C/T 
ε2/ε4 C/T C/T 
ε3/ε3 T/T C/C 
ε3/ε4 C/T C/C 
ε4/ε4 C/C C/C 
 
 
Statistical analysis 
Statistical analysis was performed using the Statistical Package for the Social Sciences 
(version 22.0; SPSS Inc, Chicago, IL) and statistical significance level was set at 0.05.  
After a careful exploration of the quality of the normalized data, a generalized linear 
model analysis (ANOVA) followed by Bonferroni post test or unpaired t-test were used 
to analyzed differences in gene expression data between groups. 
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Effects of prenatal stress (PNS) on adult 
cognitive health 
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Investigation of PNS effect on cognitive ability of wild 
type and APPswe/PSEN1dE9 offspring 
Animals 
The experiments were performed with APPswe/PSEN1dE9 (Tg) and wild type (WT) 
offspring mice at 6 and 9 months of age. 
The generation of the mouse line expressing the human mutated forms APPswe and 
PSEN1dE9 has already been described228. Animals were maintained under standard 
animal housing conditions in a twelve-hour dark-light cycle with an average 
temperature of 22 °C, relative humidity of 42% and with food and water provided ad 
libitum. All studies were performed according to protocol approved by the Animal 
Ethical Committee of École polytechnique fédérale de Lausanne (Switzerland) and by 
cantonal authorities (licence number: VD-2875). 
To obtain offspring, virgin C57BL/6 female mice were mated with APPswe/PSEN1dE9 
male mice at 8–12 weeks of age. Presence of a copulation plug was considered 
embryonic day 0.5 (E0.5). Thereafter, females were housed individually and assigned 
to a treatment group (prenatal stress or control). 
 
Prenatal stress paradigm 
Half of pregnant dams underwent prenatal stress (PNS) by chronic restraint stress 
paradigm214 during the last week of pregnancy (embryonic days E12.5 – E18.5). PNS 
consisted of daily restraint stress of the mothers, by placing the pregnant mouse in a 
well-ventilated plastic tube for 45’/day at unpredictable times of the day during the last 
week of pregnancy, a paradigm that has previously been shown to have long-lasting 
effects on adult cognitive health (J.Gräff, unpublished). Simultaneously, control time-
pregnant females were handled in the same way, but not exposed to chronic restraint 
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stress paradigm. After each restraint stress session, the animals were placed back into 
their home cage, while control dams were left undisturbed in their home cage. 
At birth, PNS-exposed pups were cross-fostered with a non-exposed stress dam and 
non-PNS (ctrl) litters were cross-fostered with another non-exposed stress dam, so that 
they spent the entire postnatal period until weaning with a control non-stressed mother. 
This allowed excluding any postnatal influence of dams that have been stressed during 
pregnancy.  
The offspring of the dams exposed to stress during pregnancy will be referred to as 
prenatally stressed (PNS), offspring of the control dams will be referred to as controls 
(ctrl). 
 
Behavioural testing 
Offspring were tested at 6 and 9 months of age. To assess overall locomotor function 
and anxiety-like behaviour, an open-field test (OFT) was performed229-231; to test for 
long-term recognition memory232,233, the novel object recognition test (NOR) was used 
(see scheme 1 for a global time line). 
The following groups of animals were included in these experiments: wild type (WT) 
and APPswe/PSEN1dE9 (Tg) male and female offspring, of both prenatal stress (PNS) 
and control (ctrl) conditions.  
Novel object recognition task (NOR) 
The NOR test was carried out in three sessions divided by an interval of twenty-four 
hours. Mice were placed in the testing room, thirty minutes before each session to 
ensure their acclimation to the room.  
During the first day (habituation session), the mouse was placed in the empty testing 
apparatus and it was allowed to explore the open-field for 10 minutes. The testing 
apparatus was a circular arena, 43 cm in diameter, with black plexiglas walls. During 
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the second day (familiarization session), the animal was free to explore two identical 
objects and during the last session (retention), one of the objects was replaced by a 
novel, unfamiliar one. This test is a one-trial task, as it does not involve learning of 
rules. In addition, it does not require reinforces and is purely based on the innate 
preference of the rodent to explore the novel object rather than the familiar one. Thus, 
a rodent that remembers the familiar object will spend more time exploring the novel 
object232,233. 
In particular, on the 2nd day of testing (familiarization session), two identical objects 
were placed in the circular arena equidistant from each other and the arena walls. The 
animal was then placed in the arena and allowed to explore the objects for 10 minutes. 
To prevent coercion to explore the objects, mice were released against the center of 
the opposite wall with its back to the objects.  
On the last day of testing (retention session), the animal was introduced in the testing 
apparatus containing one familiar object (identical to those used in the familiarization) 
and one novel object for 10 minutes. Between uses, the experimental apparatus and all 
objects were thoroughly cleansed with 5% ethanol to minimize olfactory cues. The pair 
of objects used during familiarization was randomized between each mouse and each 
group tested as well as the position of the novel object during retention (left or right). 
Locomotor activity and object investigation were video-recorded using a camera 
mounted above the testing apparatus and analyzed using EthoVision pro video tracking 
system and software (Noldus Inc., Leesburg, VA). Object exploration measures for the 
retention session were scored manually (nose-point detection) by the experimenter 
who was blinded to the treatment group.  
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Open-field task (OFT) 
During the first day of the NOR test the general locomotor activity and the exploratory 
behaviour of animals in the open-field, represented by the empty circular arena, was 
assessed229. In particular, mouse was placed in the empty open-field, facing the wall  
that is nearest to the experimenter, and allowed to explore the open-field for 10 
minutes. Between uses, the experimental apparatus was thoroughly cleansed with 5% 
ethanol to minimize olfactory cues. Distance moved and time spent in the center and in 
the periphery of the open-field were recorded using the EthoVision pro video tracking 
system and software (Noldus Inc., Leesburg, VA).   
  
49 
 
 
  
Scheme 1. Investigation of PNS effects on cognitive ability of wild type and 
APPswe/PSEN1dE9 offspring. Pregnant dams underwent daily restraint stress for 45’/day at 
embryonic days 12.5 to 18.5. At birth, PNS-exposed and ctrl pups were cross-fostered with a 
non-stressed dam to exclude any postnatal influence of dams that have been stressed during 
pregnancy. At 6 and 9 months of age the same prenatally stressed (PNS) animals have been 
compared to non-stressed (ctrl) animals for their cognitive health. The following behavioural 
tests were employed: to test for anxiety-like behaviour and animal overall locomotor function, an 
open-field test (OFT) was used; to test for memory capacities, novel object recognition test 
(NOR) was performed.   
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Investigation of acute PNS effects in wild type E18.5 
and P1 offspring  
Animals 
The experiments were carried out on wild type (WT) litter at embryonic day 18.5 
(E18.5) and at postnatal day 1 (P1). To obtain offspring, virgin C57BL/6 female mice 
were mated with C57BL/6 male at 8–12 weeks of age. Presence of a copulation plug 
was considered embryonic day 0.5 (E0.5). Thereafter, females were housed 
individually and assigned to a treatment group (prenatal stress or control). Animals 
were maintained under standard animal housing conditions in a twelve-hour dark-light 
cycle with an average temperature of 22 °C, relative humidity of 42% and with food and 
water provided ad libitum. All studies were performed according to protocol approved 
by the Animal Ethical Committee of École polytechnique fédérale de Lausanne 
(Switzerland) and by cantonal authorities (licence number: VD-2875). 
 
Prenatal stress paradigm 
Half of pregnant dams underwent prenatal stress (PNS) by the same chronic restraint 
stress paradigm214, already mentioned, during the last week of pregnancy (embryonic 
days E12.5 – E18.5) (see scheme 2 for a global time line). 
The offspring groups included in the following experiments were: wild type E18.5 
(embryonic day 18.5) embryos and P1 (postnatal day 1) pups, males and females, of 
both prenatal stress (PNS) and control (ctrl) conditions.  
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Tissue collection 
Both dams and litters were sacrificed immediately after the last session of restraint 
stress (E18.5 time point) and one day after birth/delivery (P1 time point) in order to 
investigate the acute PNS effects on HPA axis function and on brain gene expression.  
 
Blood sampling 
Blood samples were collected from dams, E18.5 embryos and P1 pups to determine 
corticosterone concentrations by ELISA assay. Blood samples were drawn from trunk 
at sacrifice using heparinized blood collection tubes (Microvette CB300, Sarstedt, DE), 
kept on ice and subsequently centrifuged at 3000 rpm for 10 minutes at 4°C. 
Subsequently, plasma was isolated, frozen down to -80°C and stored until further 
processing. 
 
Brains 
E18.5 and P1 brains were removed with the skull, immediately frozen on powdered dry 
ice and stored at -80°C.  
E18.5 whole brains were dissected from the decapitated embryos and the cerebellum 
was discarded. Subsequently, E18.5 brains were divided into three regions: a frontal 
portion (dissected by a coronal cut at the level of the first most anterior third of the 
brain), the remaining caudal portion was further cut in the middle along the dorsal-
ventral axis. The dissection was performed using a 16-gauge stainless steel needle 
based on the coordinates for developing mouse brain atlas234. Brains were maintained 
at -20°C during the whole duration of the dissection. 
The prefrontal cortex (PFC), dorsal hippocampus (HPC) and amygdala (AMY) from P1 
brains were isolated from 20 μm thick frozen coronal brain sections using brain 
punches 0.50 – 1 mm (Stoelting CO, Wood Dale, IL) basing on the coordinates for 
developing mouse brain atlas234. 
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RNA Isolation 
Total RNA from P1 brain tissue punches and E18.5 brain frontal region was carried out 
using RNeasy Tissue Mini Kit (Qiagen, Hilden, DE) according to manufacturer’s 
instructions. Absorbance measurements were made on NanoDrop 1000 (Thermo 
Scientific, Wilmington, DE) and the ratio of absorbance at 260 nm and 280 nm was 
used to assess the purity of RNA samples, further stored at -80°C. 
 
Quantitative Reverse - Transcription Polymerase Chain Reaction 
Total RNA was retrotranscribed using the qScript™ cDNA Synthesis Kit (Quantabio, 
Beverly, MA) following the protocol provided by the supplier. Quantitative Real-Time 
pcr assay (qRT-pcr) for gene expression analysis was realized using primer pairs listed 
in table 4 and SYBR Green Master Mix (Thermo Scientific, Wilmington, DE), according 
to the manufacturer's instructions. All qRT-pcr reactions were run in triplicate in 384-
well optical plates and performed in a 7900HT Fast Real-Time PCR System instrument 
(Applied Biosystems, Foster City, CA). TBP (forward: 
5’CTGGAATTGTACCGCAGCTT3’; reverse: 5’CAGTTGTCCGTGGCTCTCTT3’) and 
EEF1a (forward: 5’TCCACTTGGTCGCTTTGCT3’; reverse: 
5’CTTCTTGTCCACAGCTTTGATGA3’) were used as reference genes and fold change 
was determined by qBase relative quantification software235. 
 
Corticosterone ELISA assay 
For the quantitative determination of plasma corticosterone levels the Corticosterone 
ELISA kit (Enzo Life Science, Farmingdale, NY) was used. The assay was performed 
according to the manufacturer’s instructions. 
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Statistical analysis 
Statistical analysis was performed using the Statistical Package for the Social Sciences 
(version 22.0; SPSS Inc, Chicago, IL) and statistical significance level was set at 0.05.  
Behavioural data were analyzed by two-way analysis of variance (ANOVA) with 
genotype and PNS as factors, followed by Bonferroni post test, or by unpaired t-test 
when required. Unpaired t-test was used to analyze differences in gene expression 
data between groups. 
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Table 4. Primer pairs for quantitative real-time pcr (qRT-pcr) assay 
Target Product size 
(bp) 
Forward primer (5'-3') Reverse primer (5'-3') 
HDAC2 92 GGGACAGGCTTGGTTGTTTC GAGCATCAGCAATGGCAAGT 
HDAC1 416 CAAAGGACACGCCAAGTGTG CACAGGCAATGCGTTTGTCA 
DNMT1 91 CAGAGGAGAGAGACCAGGATAA CGTGTTACCTCTTCCAGTTTCT 
GR  90 GGCTTCTGGGTGTCACTATGG CACAGATAGTTGTGTTGTCCTTCCA 
MR 170 AGGCCGCTCAGTGTTTTCTA TACAGCTTCCACACGTCAGC 
BDNF 118 GCGCCCATGAAAGAAGTAAA TCGTCAGACCTCTCGAACCT 
BDNF IV 276 CTCCGCCATGCAATTTCC GCCTTCATGCAACCGAAG 
CX3CR1 65 CAGCATCGACCGGTACCTT GCTGCACTGTCCGGTTGTT 
CX3CL1 71 CCGCGTTCTTCCATTTGTGT GCACATGATTTCGCATTTCG 
TREM2 64 TGGGACCTCTCCACCAGTT GTGGTGTTGAGGGCTTGG 
NeuN 
(Rbfox3) 160 
GGCAAATGTTCGGGCAATTCG TCAATTTTCCGTCCCTCTACGAT 
GFAP 57 GGAGATGCGGGATGGTGAG ACCACGTCCTTGTGCTCCTG 
CNP 147 GAAGAATACGCCCAGCAGGA CAGATCACTGGGCCACAACT 
GAD67 174 CTTCTTCAGGCTCTCCCGTG CAGGAACAGGCTCGGTTCAG 
HDAC2 (histone deacetylase 2); HDAC1 (histone deacetylase 1); DNMT1 (DNA methyltransferase 1); GR 
(glucocorticoid receptor); MR (mineralcorticoid receptor); BDNF (brain derived neurotrophic factor); BDNF 
IV (brain derived neurotrophic factor exon IV); CX3CR1 (C-X3-C motif chemokine receptor 1); CX3CL1 (C-
X3-C motif chemokine ligand 1); TREM2 (triggering receptor expressed on myeloid cells 2); NeuN or 
Rbfox3 (RNA binding protein, fox-1 homolog 3); GFAP (glial fibrillary acidic protein); CNP (2',3'-cyclic 
nucleotide 3' phosphodiesterase), GAD67 (glutamate decarboxylase 67). 
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Scheme 2. Investigation of acute PNS effects in wild type E18.5 and P1 offspring. A 
second cohort of animals underwent daily restraint stress for 45’/day at embryonic days 12.5 to 
18.5. Then dams and litters were scarified immediately after the last session of restraint stress 
(embryonic day E18.5) and one day after birth/delivery (postnatal day P1) in order to investigate 
the acute PNS effects on HPA axis function and on brain gene expression. 
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Antiviral innate immune response in the brain of 
Alzheimer’s disease (AD) patients 
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Impaired antiviral gene expression in AD brains 
To reinforce the notion of an individual defective immune response against 
microorganisms in AD, the expression of genes involved in antimicrobial defences in 
the hippocampus and temporal cortex of patients with clinical and neurological defined 
diagnosis of AD and non-demented controls was investigated.  
We focused on genes involved in antiviral responses: IRF7, MED23, IFN-λ3, also 
known as IL28B, and IFN-α. A differential genetic background in these genes, 
regulating antiviral responses, was previously associated with an increased risk of 
cognitive decline and AD201. 
In particular, mRNA levels of IRF7, MED23, IL28B and IFN-α were analyzed in 29 AD 
hippocampus and 19 AD temporal brain samples.  
Most AD patients showed a down-regulation of these major antiviral immune response 
genes both in the hippocampal (figure 1) and temporal (figure 2) brain areas (table 5). 
Interestingly, mRNA levels of the transcription factor involved in innate immunity IRF7, 
MED23, a key regulator of interferon-expression, and the antiviral cytokines IL28B and 
IFN-α were hypo-expressed, at the same time, in the hippocampus of 55,2% (16/29) 
and in the temporal cortex of 26,3% (5/19) of AD patients. 
AD patients were stratified according to their down- (fold change < 1) or up- (fold 
change > 1) regulation of the analyzed genes compared to the ctrl group. Most of the 
patients showed a significant down-regulation of IRF7 (p=0.04), MED23 (p=0.0001), 
IL28B (p=0.0001) and IFN-α (p=0.0005) in the hippocampus (fig. 1), but also in the 
temporal cortex (fig. 2: IRF7, p=0.0006; MED23, p=0.005; IL28B, p=0.002; IFN-α, 
p=0.0009). A small group of AD patients showed up-regulation of MED23 (p=0.0009), 
IL28B (p=0.004) and IFN-α (p=0.002) genes only in the hippocampus (fig. 1).  
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Hippocampus 
 
Gene N Fold change 
Down-regulation in the mRNA expression IRF7 19 0.62 ± 0.06 
 
MED23  20 0.28 ± 0.04 
 
IL28B 21 0.22 ± 0.05 
 
IFN-α 19 0.22 ± 0.06 
Up-regulation in the mRNA expression IRF7 10 1.52 ± 0.14 
 
MED23 9 1.85 ± 0.15 
 
IL28B  7 2.07 ± 0.22 
 
IFN-α 9 2.39 ± 0.26 
Temporal cortex 
 
Gene N Fold change 
Down-regulation in the mRNA expression IRF7  16 0.40 ± 0.07 
 
MED23 11 0.37 ± 0.09 
 
IL28B  12 0.44 ± 0.10 
 
IFN-α  9 0.40 ± 0.07 
Up-regulation in the mRNA expression IRF7 3 1.94 ± 0.50 
 
MED23 8 1.90 ± 0.26 
 
IL28B  4 1.45 ± 0.19 
 
IFN-α  5 1.90 ± 0.35 
Table 5. Antiviral gene expression profiles in hippocampus and temporal cortex of AD 
patients. Values are given as fold change ± SEM 
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Figure 1. Hippocampal differential expression of antiviral response genes in AD 
patients and healthy individuals. Fold change (qRT-pcr 2-∆∆Ct method) of IRF7 (A), 
MED23 (B), IL28B (C), IFN-α (D), normalized to two reference genes (CYC1 and EIF4A2) and 
relative to non-demented healthy individuals (ctrl), in hippocampus of patients with clinical and 
neurological defined diagnosis of AD. Values are given as fold change ± SEM. *p<0.05; 
**p<0.01; ***p<0.001 (unpaired t-test).    
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Figure 2. Temporal differential expression of antiviral response genes in AD 
patients and healthy individuals. Fold change (qRT-pcr 2-∆∆Ct method) of IRF7 (A), 
MED23 (B), IL28B (C), IFN-α (D), normalized to two reference genes (CYC1 and EIF4A2) and 
relative to non-demented healthy individuals (ctrl), in temporal cortex of patients with clinical and 
neurological defined diagnosis of AD. Values are given as fold change ± SEM. **p<0.01; 
***p<0.001 (unpaired t-test).    
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Single nucleotide polymorphisms (SNPs) of antiviral 
genes and their effects on gene expression profiles in 
AD brains 
DNA from brain tissues (hippocampus and temporal cortex) was extracted and AD 
patients (table 1 and 2) were genotyped for APOE ε allele (rs429358 and rs7412; table 
3) and for SNPs of IRF7 (rs6598008), MED23 (rs3756784), IL28B (rs12979860) genes 
(tables 6 and 7) that have been previously associated with increased risk of cognitive 
decline and AD201. We analyzed these genetic variants in order to investigate a 
potential effect of these SNPs on the brain antiviral gene expression profiles.      
The presence of APOE ε4 allele influenced the hippocampus mRNA levels of MED23, 
IL28B and IFN-α. The relative expression of MED23, the antiviral component of the 
Mediator complex, IL28B and IFN-α, belonging to the group of type III and I IFNs 
respectively, were significantly lower in ε4 allele carrier AD patients when compared to 
ε4 allele non carriers (MED23, p=0.010; IL28B, p=0.010; IFN-α, p=0.0076; figure 3B, C, 
D).  
 
APOE ε4 carrier AD patients showed also significantly lower temporal mRNA levels of 
MED23 gene than that of APOE ε4 non carriers (p=0.04; figure 4B). However, temporal 
mRNA expression levels of IL28B (p=0.88) and IFN-α (p=0.06) of APOE ε4 carriers did 
not significantly differ from that of non carrier AD patients (figure 4C and D). 
mRNA levels of antiviral factors from hippocampus and temporal cortex samples from 
AD patients were also stratified according to IRF7 (rs6598008) (figures 5 and 6), 
MED23 (rs3756784) (figures 7 and 8), IL28B (rs12979860) (figures 9 and 10) 
genotypes (tables 6 and 7). 
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AD A carriers of IRF7 SNP (rs6598008) showed significantly lower mRNA relative 
levels of IRF7 (p=0.027), MED23 (p=0.005), IL28B (p=0.02) and IFN-α (p=0.006) in 
hippocampus than those observed from GG carriers (figure 5). However, these 
differences were not observed in temporal cortex from AD samples (figure 6). 
The effects of MED23 (rs3756784) and IL28B (rs12979860) SNPs on AD brain antiviral 
gene expression were also investigated. However, no statistically significant 
differences in mRNA profiles were found between G carriers and G non carriers of 
MED23 gene variant, and between T carrier and T non carrier patients of IL28B SNP, 
as shown from hippocampus (figure 7 and 9) and temporal cortex samples (figures 8 
and 10). 
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 Hippocampus 
 
APOE genotype 
 
ε2/ε3 ε3/ε3 ε3/ε4 ε4/ε4 ε4 non carrier ε4 carrier 
 
N % N % N % N % N % N % 
 
2 6.9 7 24.1 15 51.7 5 17.2 9 31 20 69 
 
IRF7 rs6598008 genotype  
 
AA GA GG    A carrier G carrier 
 
N % N % N %    N % N % 
 
5 17.2 16 55.2 8 26.6 
 
 
21 72.4 24 82.8 
 
MED23 rs3756784 genotype 
 
GG GT TT    G carrier T carrier 
 
N % N % N %    N % N % 
 
1 3.4 11 37.9 17 58.6 
 
 
12 41.4 28 96.6 
 
IL28B rs12979860 genotype 
 
TT CT CC    T carrier C carrier 
 
N % N % N %    N % N % 
 
3 10.3 14 48.3 12 41.4 
 
 
17 58.6 26 89.7 
Table 6. Genotype and allele distribution of SNPs of APOE, IRF7, MED23 and IL28B genes 
from AD patients whose hippocampus samples have been analyzed. 
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Temporal cortex 
 
APOE genotype    
 
ε2/ε3 ε3/ε3 ε3/ε4 ε4/ε4  ε4 non carrier ε4 carrier 
  N % N % N % N % N % N % 
 
1 5.3 10 52.6 7 36.8 1 5.3 11 57.9 8 42.1 
 
IRF7 rs6598008 genotype 
 
AA GA GG    A carrier G carrier 
 
N % N % N %    N % N % 
 
1 5.3 11 57.9 7 36.8 
 
 
12 63.2 18 94.7 
 
MED23 rs3756784 genotype 
 
GG GT TT    G carrier T carrier 
 
N % N % N %    N % N % 
 
2 10.5 5 26.3 12 63.2 
 
 
7 36.8 17 89.5 
 
IL28B rs12979860 genotype 
 
TT CT CC    T carrier C carrier 
 
N % N % N %    N % N % 
 
2 10.5 9 47.4 8 42.1 
 
 
11 57.9 17 89.5 
Table 7. Genotype and allele distribution of SNPs of APOE, IRF7, MED23 and IL28B genes 
from AD patients whose temporal cortex samples have been analyzed. 
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Figure 3. Effect of APOE ε4 allele on antiviral immune gene expression from AD 
hippocampus samples. qRT-pcr data showing relative expression (2-∆Ct values using CYC1 
and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) from 
hippocampus of AD patients grouped in APOE ε4 non carrier/or APOE ε4 carrier. Data from 
each group are shown as a box and whiskers plot with the ends of the whiskers represent the 
minimum and maximum data values, the horizontal line represents the median and the “+” 
represents the mean relative expression values. *p<0.05; **p<0.01 (unpaired t-test).    
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Figure 4. Effect of APOE ε4 allele on antiviral immune gene expression from AD 
temporal cortex samples. qRT-pcr data showing relative expression (2-∆Ct values using 
CYC1 and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) from 
temporal cortex of AD patients grouped in APOE ε4 non carrier/or APOE ε4 carrier. Data from 
each group are shown as a box and whiskers plot with the ends of the whiskers represent the 
minimum and maximum  data values, the horizontal line represents the median and the “+” 
represents the mean relative expression values. *p<0.05 (unpaired t-test).    
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Figure 5. Effect of IRF7 SNP (rs6598008) on antiviral immune gene expression 
from AD hippocampus samples. qRT-pcr data showing relative expression (2-∆Ct values 
using CYC1 and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) 
from hippocampus of AD patients grouped in AA, GA, GG genotypes on the left panels and in A 
carrier/or A non carrier on the right panels. Data from each group are shown as a box and 
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whiskers plot with the ends of the whiskers represent the minimum and maximum  data values, 
the horizontal line represents the median and the “+” represents the mean relative expression 
values. *p<0.05; **p<0.01 (unpaired t-test; one-way ANOVA followed by Bonferroni post test).  
 
 
 
 
Figure 6. Effect of IRF7 SNP (rs6598008) on antiviral immune gene expression 
from AD temporal cortex samples. qRT-pcr data showing relative expression (2-∆Ct values 
using CYC1 and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) 
from temporal cortex of AD patients grouped in A carrier/or A non carrier. Data from each group 
are shown as a box and whiskers plot with the ends of the whiskers represent the minimum and 
maximum data values, the horizontal line represents the median and the “+” represents the 
mean relative expression values. Unpaired t-test.   
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Figure 7. Effect of MED23 SNP (rs3756784) on antiviral immune gene expression 
from AD hippocampus samples. qRT-pcr data showing relative expression (2-∆Ct values 
using CYC1 and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) 
from hippocampus of AD patients grouped in G carrier/or G non carrier. Data from each group 
are shown as a box and whiskers plot with the ends of the whiskers represent the minimum and 
maximum  data values, the horizontal line represents the median and the “+” represents the 
mean relative expression values. Unpaired t-test.     
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Figure 8. Effect of MED23 SNP (rs3756784) on antiviral immune gene expression 
from AD temporal cortex samples. qRT-pcr data showing relative expression (2-∆Ct values 
using CYC1 and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) 
from temporal cortex of AD patients grouped in GG, GT, TT genotypes on the left panels and in 
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G carrier/or G non carrier on the right panels. Data from each group are shown as a box and 
whiskers plot with the ends of the whiskers represent the minimum and maximum  data values, 
the horizontal line represents the median and the “+” represents the mean relative expression 
values. Unpaired t-test; one-way ANOVA followed by Bonferroni post test.  
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Figure 9. Effect of IL28B SNP (rs12979860) on antiviral immune gene expression 
from AD hippocampus samples. qRT-pcr data showing relative expression (2-∆Ct values 
using CYC1 and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) 
from hippocampus of AD patients grouped in TT, CT, CC genotypes on the left panels and in T 
carrier/or T non carrier on the right panels. Data from each group are shown as a box and 
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whiskers plot with the ends of the whiskers represent the minimum and maximum  data values, 
the horizontal line represents the median and the “+” represents the mean relative expression 
values. Unpaired t-test; one-way ANOVA followed by Bonferroni post test.  
 
 
 
 
Figure 10. Effect of IL28B SNP (rs12979860) on antiviral immune gene expression 
from AD temporal cortex samples. qRT-pcr data showing relative expression (2-∆Ct values 
using CYC1 and EIF4A2 as reference genes) of IRF7 (A), MED23 (B), IL28B (C), IFN-α (D) 
from temporal cortex of AD patients grouped in T carrier/or T non carrier. Data from each group 
are shown as a box and whiskers plot with the ends of the whiskers represent the minimum and 
maximum  data values, the horizontal line represents the median and the “+” represents the 
mean relative expression values. Unpaired t-test.       
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Effects of prenatal stress (PNS) on adult 
cognitive health 
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Long-term effects of prenatal stress (PNS) on cognitive 
ability of WT and APPswe/PSEN1dE9 offspring 
 
Basal locomotion is not altered by prenatal stress (PNS) in wild type and 
APPswe/PSEN1dE9  
The open-field test (OFT) is a common measure of exploratory behaviour and general 
locomotor activity in rodents. The OFT is used to assess locomotor activity level as a 
“control” experiment for behavioural tests that involve activity231,236,237 but it also 
provides an initial screen for mouse anxiety-related behaviour230. Rodents typically 
spend a significantly greater amount of time exploring the periphery of an open-field 
(empty arena), usually in contact with the walls (thigmotaxis), than the unprotected 
center area. The proportion of time spent  avoiding  the center of the arena is therefore 
taken as a measure of  anxiety-like behaviour229. 
At adulthood, at 6 months and 9 months of age, PNS-exposed wild type (WT) and 
APPswe/PSEN1dE9 (Tg) offspring were compared to non-stressed ones (ctrl) for their 
locomotor activity and exploratory behaviour in the open-field context, and total 
distance moved and time spent in the center and the periphery of the open-field arena 
were measured. 
At 6 months, animal locomotor activity was not affected (figure 11, A and B) and time 
spent exploring central and peripheral zone of the open-field arena didn’t reveal 
significant differences between prenatally stressed and control offspring both in WT 
and Tg groups (fig. 11, C and D). Examination of the open-field center time exploration 
as a preliminary screen for anxiety-like behaviour revealed no significant PNS 
differences both in male and female offspring.   
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Likewise, at 9 months of age, the anxiety-like behavioural measures didn’t highlight any 
differences due to PNS. Animal general locomotor activity was not affected (figure 12, 
A and B) and central and/or peripheral zone activity within the open-field arena didn’t 
reveal significant differences between prenatally stressed and control offspring both in 
WT and Tg mice (figure 12, C and D).  
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Figure 11. No effect of PNS on open-field exploration offspring at 6 months of 
age. Data show locomotor activity during OFT of prenatally stress and control male (A) and 
female (B) offspring at 6 months of age. Panels C and D show time spent exploring the center 
and the periphery of the open-field by prenatally stress and control male (C) and female (D) 
offspring at 6 months of age. No significant PNS differences on central and peripheral zone 
activity were found.  
Male offspring: WT ctrl n=8; WT PNS n=8; Tg ctrl n=16; Tg PNS n=11. Female offspring: WT 
ctrl n=11; WT PNS n=13; Tg ctrl n=14; Tg PNS n=8. Data are shown as mean ± SEM. ** p<0.01 
(two-way ANOVA followed by Bonferroni post test).                                                                                                                                                                                                                                                                     
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Figure 12. No effect of PNS on open-field exploration offspring at 9 months of 
age. Data show locomotor activity during OFT of prenatally stress and control male (A) and 
female (B) offspring at 9 months of age. Panels C and D show time spent exploring the center 
and the periphery of the open-field by prenatally stress and control male (C) and female (D) 
offspring at 6 months of age. No significant genotype / PNS differences on central and 
peripheral zone activity were found.  
Male offspring: WT ctrl n=4; WT PNS n=2; Tg ctrl n=6; Tg PNS n=4. Female offspring: WT ctrl 
n=2; WT PNS n=9; Tg ctrl n=6; Tg PNS n=2. Data are shown as mean ± SEM. Two-way 
ANOVA followed by Bonferroni post test.                                                                                                                                                                                                                                                                     
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PNS accelerates long-term memory deficit in APPswe/PSEN1dE9  
The novel object recognition (NOR) test was used to assess the potential effect of PNS 
on long-term recognition memory of wild type (WT) and APPswe/PSEN1dE9 (Tg) 
offspring at 6 and 9 months of age. We performed this behavioural test to characterize 
the potential cognitive impairment caused by PNS in APPswe/PSEN1dE9 mice at early 
stages of amyloid-β (Aβ) deposition238, where recognition memory is normally 
comparable between Tg and WT animals239. NOR test is a typical behavioural test 
used to assess memory function in AD mouse model240. This test is based on the 
spontaneous tendency of rodents to spend more time exploring a novel object than a 
familiar one. The choice to explore the novel object reflects the use of learning and 
recognition memory232,233. 
Familiar object exploration time (Time Familiar, TF) and novel object exploration time 
(Time Novel, TN) was scored manually with the EthoVision software (Noldus Inc., 
Leesburg, VA) by the experimenter blinded to the treatment group. Exploration of an 
object was defined as directing the nose toward the object, while climbing onto the 
object (unless active object sniffing is observed) or chewing the object didn’t qualify as 
exploration. Mice that didn’t satisfy the criterion of 20 s exploration time of both items 
within familiarization and/or retention test sessions were excluded from the following 
analyses.   
We used the Discrimination Index (DI) and Recognition Index (RI) as two estimations of 
recognition process and to measure long-term recognition memory of each animal 
group. The DI [DI = (TN-TF)/(TN+TF)] is a measure of discrimination between the novel 
and familiar objects and it calculates the difference between exploration time for novel 
and familiar objects, dividing it by the total amount of exploration time during retention 
session. The RI [RI = TN/(TN +TF)] is the time spent investigating the novel object 
relative to the total exploration time and it is considered the main index of retention232. 
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In most cases, mice were able to distinguish the novel from the familiar object both at 6 
(figure 13, A and B) and 9 (figure 14, A and B) months, indicating a functionally intact 
memory as shown by DI higher than 0. 
When comparing discrimination performance between groups, at 6 months we 
observed a significant decreased novel object recognition of prenatally stressed Tg 
males, and not of prenatally stressed WT males, when compared to non-stressed 
controls (fig.13 A, F(1,39)=5.845, p<0.05), while the decrease of DI was not statistically 
significant in prenatally stressed female offspring (fig.13 B). Prenatally stressed Tg 
male offspring demonstrated also a significant memory deficit for the familiar object 
(fig.13 C, F(1,39)=5.884, p<0.05; fig.13 E, F(1,39)=8.070, p<0.05). On the other hand, 
female offspring, both WT and Tg, showed intact object recognition memory (fig. 13, D 
and F) at 6 months. Object recognition memory was not significantly influenced by 
genotype, as indicated by the absence of significant differences between WT and Tg 
groups, after two-way ANOVA analysis. It seems that PNS influenced memory 
performance of Tg male offspring by accelerating the onset of the cognitive deficts.  
At 9 months a smaller number of animals per group were tested because some mice 
died before reaching 9 months of age and a fraction of the animal cohort had not 
reached the 9 month age yet. No significant difference of recognition performance 
between prenatally stressed Tg male offspring and control was found. We observed a 
decreased discrimination ability of PNS WT males compared to ctrl WT and of ctrl Tg 
males when compared to the ctrl WT ones (figure 14 A). On the other hand, PNS-
exposed Tg female offspring showed an increasing DI and RI trend (fig. 14, B and D) 
even if significant differences were not found. The improved discrimination ability of 
PNS Tg female offspring compared to the corresponding ctrl, as indicated by their 
significant decreased exploration of familiar object (fig. 14 F, F(1,15)=5.042, p<0.05), 
points to a possible PNS positive impact on Tg female recognition performance.  
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Figure 13. Effect of PNS on long-term recognition memory at 6 months of age. 
Discrimination Index (A, B), Recognition Index (C, D), exploration time of familiar and novel 
objects (E, F) during the retention session of NOR test at 6 months in prenatally stressed and 
control animals. Discrimination Index: (time novel – time familiar)/(time novel + time familiar); 
Recognition Index (time novel)/(time novel + time familiar). Male offspring: WT ctrl n=8; WT PNS 
n=8; Tg ctrl n=16; Tg PNS n=11. Female offspring: WT ctrl n=11; WT PNS n=13; Tg ctrl n=14; 
Tg PNS n=8. Data are shown as mean ± SEM. *p<0.05 (two-way ANOVA followed by 
Bonferroni post test).  
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Figure 14. Effect of PNS on long-term recognition memory at 9 months of age. 
Discrimination Index (A, B), Recognition Index (C, D), exploration time of familiar and novel 
objects (E, F) during the retention session of NOR test at 9 months in prenatally stressed and 
control animals. Discrimination Index: (time novel – time familiar)/(time novel + time familiar); 
Recognition Index (time novel)/(time novel + time familiar). Male offspring: WT ctrl n=4; WT PNS 
n=2; Tg ctrl n=6; Tg PNS n=4. Female offspring: WT ctrl n=2; WT PNS n=9; Tg ctrl n=6; Tg PNS 
n=2. Data are shown as mean ± SEM. *p<0.05 (two-way ANOVA followed by Bonferroni post 
test).  
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Early neurobiological effects of prenatal stress (PNS) in 
embryos at E18.5 and pups at P1 
 
Corticosterone secretion displays sex-dependent alterations in response 
to PNS-exposure 
Pregnant dams underwent prenatal stress (PNS) by the same chronic restraint stress 
paradigm214 mentioned in Materials and Methods chapter during the last week of 
pregnancy (embryonic days E12.5 – E18.5) (see scheme 2). The offspring groups 
included in the following experiments were: wild type E18.5 (embryonic day 18.5) 
embryos and P1 (postnatal day 1) pups, males and females, of both PNS and control 
conditions. Blood samples of these animals were collected immediately after the last 
session of restraint stress (embryonic day 18.5) and one day after delivery (postnatal 
day - P1) in order to measure corticosterone (CORT) plasma levels and to investigate 
the potential acute effects of PNS on HPA axis function.  
First of all, we planned to determine CORT levels in plasma of stressed (PNS) and ctrl 
dams immediately after the last day of restraint stress paradigm (E18.5 time point) and 
one day after delivery (P1 time point) to assess whether the PNS paradigm had 
properly worked. As indicated by the plasma CORT surge of PNS dams at E18.5, 45 
minutes after the beginning of the last stress session, we verified the validity of the 
PNS paradigm (figure 15 A). Moreover, the obtained data showed an increase of 
CORT plasma levels in female embryos measured at this time point (fig. 15 A). 
Embryonic CORT plasma levels upon-PNS (E18.5 time point) were significantly 
influenced by PNS exposure (fig. 15 A, two-way ANOVA: PNS factor, F(1,19)=9.23, 
p<0.05).  
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Furthermore, a sex effect (F(1,18)=26.60, p<0.0001), a PNS-exposure effect 
(F(1,18)=11.10, p<0.01) and also a sex X PNS-exposure effect (F(1,18)=18.06, 
p<0.01) were observed at rest in P1 offspring. In particular, PNS significantly increased 
basal CORT plasma levels only in male P1 pups (fig. 15 B).  . 
 
 
Figure 15. Serum corticosterone concentration after PNS and at rest. A) 
Corticosterone (CORT) plasma levels in stressed and non-stressed (ctrl) mothers and E18.5 
embryos. Blood samples were collected immediately after restraint stress on day E18.5. B) 
Corticosterone (CORT) plasma levels in stressed and ctrl mothers and P1 offspring. Blood 
samples were collected one day after delivery (postnatal day 1). Data are shown as mean ± 
SEM. *p<0.05; ***p<0.001(two-way ANOVA followed by Bonferroni post test). 
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PNS affects hippocampal gene expression profiles in P1 females     
To identify early effects of PNS on brain gene expression and subsequently clarify 
trigger mechanisms of the potential cognitive impairment caused by PNS during 
ageing, we analysed expression levels of a number of genes in PNS E18.5 embryos 
and P1 pups compared to non-PNS controls. 
During the prenatal period, the HPA axis is particularly susceptible to programming by 
glucocorticoids (GCs), that are important for normal maturation in most fetal organs 
including the developing brain208. Moreover, early-life stressful events produce long-
term effects on the developing brain, in part mediated by epigenetic modification241-244, 
increasing subsequent risk of neuropsychiatric disorders throughout life245 which are all 
virtually associated with changes in neuroplasticity and neuroinflammatory 
processes246,247. Based on these notions, we focused on genes implicated in 
epigenetic regulation, stress-response, neuroplasticity and microglia synaptic pruning 
pathways. In addition, we determined relative mRNA expression of genes that are 
specifically expressed in different brain cell subtypes. 
E18.5 brain area of interest was the frontal part, while P1 brain areas analyzed were 
dorsal hippocampus (HPC), prefrontal cortex (PFC) for cognitive functions, and 
amygdala (AMY) for anxiety-like and impulsive behaviours.  
Acute PNS consequences on brain gene expression were different depending on the 
timing and brain region. Moreover, the PNS impact on developing brain gene 
expression was different between male and female offspring, since it significantly 
affected brain gene expression only of P1 females.  
In particular, PNS mostly affected gene expression in the hippocampus (figure 16), 
where down-regulation of genes encoding for the mineralcorticoid receptor (MR) 
(p=0.018), the chemokine C-X3-C motif receptor 1 (CX3CR1) (p=0.048) and the DNA 
methyltransferase 1 (DNMT1) (p=0.012) was observed. On the other hand, histone 
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deacetylase-1 (HDAC1) (p=0.007) gene was up-regulated in hippocampus of P1 
female offspring prenatally exposed to stress (fig. 16 A). The tendency for the up-
regulation of HDAC1 gene (p=0.055) was already present in the frontal brain region of 
PNS female embryos even if, in this case, the relative expression difference between 
PNS and ctrl groups was not statistically significant (figure 17 A). 
P1 PNS female offspring showed a significant decreased mRNA level of glucocorticoid 
receptor (GR) (p=0.004) and BDNF exon IV (BDNF IV) (p=0.02) genes, in the 
prefrontal cortex (figure 18 B) and amygdala (figure 19 B) respectively. An increased 
expression of the glial fibrillary acidic protein (GFAP) gene (p=0.037) (fig. 18 D), an 
astrocytic marker, was also present in the prefrontal cortex of P1 PNS females.  
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Figure 16. Gene expression analyses in dorsal hippocampus (HPC) of prenatally 
stressed P1 wild type offspring. qRT-pcr data show relative expression (2-∆∆Ct method), 
using EEF1 and TBP as reference genes, of (A) epigenetic regulation, (B) stress-response, (C) 
neuroplasticity and microglia synaptic pruning genes and (D) brain cell subtype markers. 
F, female offspring: WT ctrl n=3/4; WT PNS n=5/6. M, male offspring: WT ctrl n=4; WT PNS 
n=4. Data are shown as mean ± SEM.  *p<0.05; ** p<0.01 (unpaired t-test).                                                                                                                                                                                                
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Figure 17. Gene expression analyses in frontal region of prenatally stressed 
E18.5 wild type embryos. qRT-pcr data show relative expression (2-∆∆Ct method), using 
EEF1 and TBP as reference genes, of (A) epigenetic regulation, (B) stress-response, (C) 
neuroplasticity and microglia synaptic pruning genes and (D) brain cell subtype markers. 
F, female embryos: WT ctrl n=4; WT PNS n=6. M, male embryos: WT ctrl n=4/7; WT PNS 
n=3/6. Data are shown as mean ± SEM. Unpaired t-test. 
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Figure 18. Gene expression analyses in prefrontal cortex (PFC) of prenatally 
stressed P1 wild type offspring. qRT-pcr data show relative expression (2-∆∆Ct method), 
using EEF1 and TBP as reference genes, of (A) epigenetic regulation, (B) stress-response, (C) 
neuroplasticity and microglia synaptic pruning genes and (D) brain cell subtype markers. 
F, female offspring: WT ctrl n=2; WT PNS n=3/6. M, male offspring: WT ctrl n=4; WT PNS n=4. 
Data are shown as mean ± SEM. *p<0.05; ** p<0.01 (unpaired t-test).                            
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Figure 19. Gene expression analyses in amygdala (AMY) of prenatally stressed 
P1 wild type offspring. qRT-pcr data show relative expression (2-∆∆Ct method), using EEF1 
and TBP as reference genes, of (A) epigenetic regulation, (B) stress-response, (C) 
neuroplasticity and microglia synaptic pruning genes and (D) brain cell subtype markers. 
F, female offspring: WT ctrl n=2; WT PNS n=4. M, male offspring: WT ctrl n=4; WT PNS n=4. 
Data are shown as mean ± SEM. *p<0.05 (unpaired t-test).                           
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Discussion 
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Antiviral innate immune response in the brain of 
Alzheimer’s disease (AD) patients 
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Alzheimer's disease (AD) is a progressive, degenerative disorder of the CNS and 
represents the most common form of dementia. Neurodegenerative diseases primarily 
occur in the later stages of life, positioning ageing as an essential co-factor in their 
pathogenesis248. Ageing affects all physiological systems, of which one of the most 
important is the immune system249. No all immune responses show the same rate of 
ageing or senescence. Innate immunity is partially affected by human ageing, while 
adaptive immune response progressively decline with age149.  
Over the past years, GWA studies of sporadic AD cases have shown that several 
genes with immune regulatory functions were associated with differential risk of AD75-
77,80,82,90. In this context, it should be mentioned that the well known genetic risk factor 
for AD, the APOE ε4 allele, may be involved in the dysregulation of phagocytosis and 
inflammatory responses in the brain93. However, the role of innate immunity in the 
pathogenesis and in clinical history of AD remains to be clarified.  
AD is a multi-factorial and heterogeneous disease and among environmental factors 
likely associated with it, persistent virus infections and the progressive decline of 
immune competence with advancing age may play a pivotal role122. The ageing of the 
immune system is a dynamic process which partially reflects adaptation of the immune 
response to an evolving pathogen milieu249,250. Several studies suggest that ageing is 
associated with increased memory T cell compartment in part due to continuous 
consumption of existing immunological resources by persistent infections249,251. 
Persistent virus infections continue mainly because the viral source is not completely 
removed by the immune system and usually reside inside certain cell types as immune, 
neuronal and epithelial cells249. Viruses of the herpes family, largely and commonly 
present in old individuals, undergo frequent cycles of reactivation and latency over the 
life-time and lead to the accumulation of memory T cells. However, the immune system 
is not able to completely eradicate these viruses and repeated antigen stimulation 
induced by them activates a peripheral chronic inflammatory response that 
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progressively impairs defensive immune ability and aggravates the senescence of the 
immune system156,249.  
Chronic subclinical infections represent relevant environmental factors for the clinical 
progression of AD122. A declining immune system resulting in a chronic brain 
inflammation might therefore contribute to neurodegeneration122,149.  
The peripheral immune dysfunction induced by persistent subclinical infections may 
impair brain functioning by priming microglia and/or by increasing the leaking of the 
BBB122. An altered resolution of inflammatory state has been recently found in the brain 
of AD patients and such impairment correlated with cognitive performances252. 
Moreover, elevated levels of CNS and CSF inflammatory markers have been reported 
in preclinical stages of AD253. Recent findings reinforced the notion that brain 
inflammation, as assessed by CSF markers, increases in normal ageing and is 
associated with markers of neurodegeneration in the preclinical stages of AD254. 
Neuroinflammation in Alzheimer’s disease may be partially caused by already primed 
microglia that may easily switch to a damaging M1 phenotype255,256. Animal studies 
from aged mice showed an exaggerated brain inflammatory and oxidative stress 
responses to peripheral stimuli257, increased concentrations of interleukin 1β (IL1β) in 
the CNS and neuronal apoptosis in the ME7 prion mouse, after peripheral challenge 
with lipopolysaccharide (LPS) or polyinosinic-polycytidylic acid (polyI:C)258-260. 
AD microglia might also be primed by infectious agents challenging the CNS as viruses 
belonging to the herpes family. There are several studies implicating HSV-1 in the 
etiology of AD133,134,136,261. The first observations of HSV-1 in AD brains were reported 
almost thirty years ago142. HSV-1 is a ubiquitous virus that affects more than 80% of 
people over 65 worldwide. It is a neurotropic double-stranded DNA virus that primarily 
infects epithelial cells of oral and nasal mucosa. Here, HSV-1 undergoes lytic 
replication; the newly produced viral particles thereafter enter sensory neurons and, by 
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axonal transport, reach the trigeminal ganglion where usually establish a latent 
infection. HSV-1 undergoes periodic reactivation cycles in which the newly formed viral 
particles are transported back to the site of primary infection through the sensory 
neurons, causing typical epithelial lesions. However, the bipolar trigeminal ganglion 
neurons also project to the trigeminal nuclei located in the brainstem. From here, 
neurons project to the thalamus to finally reach the sensory cortex. This is the path 
through which the reactivated virus may reach the CNS, where it may cause acute 
neurological disorders like encephalitis or a mild, clinically asymptomatic infection, or 
establish a life-long latent infection149,262. A reactivation of HSV-1 infection, assessed by 
increased serum levels of specific anti-HSV-1 antibodies, was found associated with an 
increased AD risk in a longitudinal study on 3432 elderly151. 
Other pathogens have been implicated in the pathogenesis of AD135,164 and chronic 
infections, in a context of senescent immune system, are emerging risk factors for this 
disease143. A recent review by Harris et al. confirmed that infection agents such as 
CMV, HSV-1, HHV-6, Helicobacter pylori, Chlamydophila pneumonia and several 
periodontal pathogens are able to induce the production of peripheral proinflammatory 
cytokines that, by crossing the BBB, might promote neurodegeneration135. In addition, 
spirochetes have also been proposed to be associated with AD137. Moreover, oral 
infections have been recently suggested as potential causes of BBB disruption and 
brain inflammation. These pathogens may also infect the brain via trigeminal and/or 
olfactory nerves135,263.  
On the other hand, the Aβ peptide has been shown to function as a defensive immune 
factor in the brain264. The physiological function of the APP and the biological role of its 
proteolytic derivatives are still uncertain265. In mice and in cell culture, Aβ deposition 
and tau abnormalities, typical of AD, are observed after infection with HSV-1266-275 or 
bacteria276-279 and a direct interaction between APP and HSV-1 has been reported154. 
Recent investigations confirmed that Aβ is an antimicrobial peptide (AMP) with potent 
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activity against bacteria and yeast264 but also against viruses. Experimental evidences 
showed that Aβ peptides inhibit influenza virus280 and HSV-1281,282 replication. Carrano 
and colleagues suggested that APP and/or its cleaved products are necessary to 
mount a complete and effective innate immune response to inflammatory injury in the 
brain, being involved in microglia activation283. These data reinforced the notion that the 
Aβ peptide might be a component of the innate immunity against brain pathogens, 
using a classic AMP mechanism characterized by reduce microbial adhesion to host 
cells, and agglutination and entrapment of microbes by Aβ fibrils284,285.  
The above findings are compatible with the hypothesis that neurodegenerative 
mechanisms associated with clinical AD might be in part induced or affected by chronic 
infections of the ageing brain. In previous publications, Licastro et al. discussed genetic 
data from four AD GWA studies75-77,90. From these investigations a set of SNPs 
associated with AD emerged and they suggested that the concomitant presence of 
these SNPs might result in a genetic signature predisposing to AD, via complex and 
diverse mechanisms, each contributing to an increased individual susceptibility to 
herpes virus infection88,89. Therefore, neurotropic herpes viruses may directly infect and 
damage selected brain areas in genetically susceptible elderly and induce 
neurodegenerative mechanisms.  
However, it is also relevant how the host responds to these microorganisms. In fact, 
the individual genetic background plays a pivotal role in the maintenance of the chronic 
inflammation both in the brain and in the peripheral tissues149. In this context, as 
already mentioned, GWA studies in AD showed that several immune factors were 
associated with increased risk of the disease, but each single immune gene showed a 
low OR (odds ratio < 1.7) of association with AD. The only exception was the APOE ε4 
allele, which is also a well known susceptibility factor for several virus infections286-288. 
The weak association of immune genes with AD can be simply explained as no 
immune factor is the cause of the disease. Nevertheless, the concomitant presence of 
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several genetic factors in the same individual might show a stronger association and 
individual infection susceptibility may be affected by the concomitant presence of 
alleles resulting in decreased immune efficiency88,89. As infections appear to be 
involved in AD pathogenesis, the link between a given pathogen and the host 
susceptibility to its infectivity might be one missing link in the clinical progression from 
cognitive decline to AD149.  
At the present, little is known about the efficiency of immune factors involved in 
antimicrobial defences in the human brain. 
In the current study, we have attempted to evaluate the role of interferon regulatory 
factor (IRF) 7, mediator complex (MED) 23, interferon (IFN)-λ3, also known as IL28B, 
and IFN-α genes in the brain of AD patients as well as the potential association of their 
expression in hippocampus and temporal cortex. Since our recent findings showed that 
diverse genetic backgrounds in genes regulating antiviral responses were associated 
with an increased risk of AD88,89,164,201, the focus of this thesis was set on SNPs of 
APOE gene and SNPs located upstream of the IRF7, MED23 and IL28B genes, and 
their potential effect on the brain gene expression profiles.  
IFN-α and IL28B are interferons belonging to the type I and III IFN family respectively 
and they induce a strong antiviral state in responsive cells. Whereas almost all 
nucleated cells respond to type I IFNs, responses to type III IFNs are restricted to 
tissues with an increased propensity to viral exposure and infection, such as those at 
mucosal surfaces190. There is mounting evidence for a role of the type III IFNs in the 
regulation of virus infection188, particularly in the case of HCV infection289,290. Moreover, 
individuals with recurrent HSV-1 reactivation have been shown to be deficient in IFN-λ 
expression291 and it has also been found an association between a SNP in the 
promoter of IL28B and ethnically Italian patients suffering recurrent and severe 
reactivations of HSV-1-related oral herpes outbreaks196. Type I IFNs, mainly produced 
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by HSV-infected keratinocytes292 and pDCs (plasmacytoid dendritic cells)293, inhibit the 
spread from neurons to epithelial cells and between epithelial cells294. Type III IFNs are 
also able to directly inhibit HSV-1 infection in primary neurons, astrocytes, 
macrophages and dendritic cells295,296 and are mainly expressed by myeloid dendritic 
cells (mDC) and monocyte-derived macrophage191. Since primary HSV-1 infection and 
reactivation affect skin and mucosa in the majority of cases, IFN-λ may play a role in 
the control of HSV-1 infection and reactivation.  
Using a genome-wide approach to identify host factors that functionally influence HSV-
1 infection in vitro, Griffiths and collegues identified a subunit of the Mediator multi-
protein complex, Med23, as a key regulator of IFN-λ induction and of control of HSV-1 
infection both in vitro and in vivo196. This study identified Med23 as a novel antiviral 
factor which acts as a key regulator of IFN-λ expression by interacting with and 
enhancing the activity of IRF7. Investigations into the mechanism of action revealed 
that Med23 inhibits HSV-1 replication by preferentially inducing a IFN-λ response at the 
mRNA and protein level. This IFN-λ induction was mediated via a direct interaction with 
IRF7, which resulted in a synergistic increase in IFN-λ expression. Interestingly, the 
inhibitory effect of Med23 was specific to HSV-1196. The failure to induce IFN-λ and 
thereby control HSV-1 in the brain may be a potential cofactor for the development of 
dementia of Alzheimer’s type89. 
The study presented here showed that the expression of genes involved in 
antimicrobial defences, especially against virus infections, such as IRF7, MED23, 
IL28B and IFN-α was defective in the majority of AD brains. There was a tendency for 
the down-regulation of these antiviral innate response genes in the brain of AD 
patients, particularly accentuated in the hippocampus area. The defective brain gene 
expression found in most AD patients might compromise the efficiency of immune 
responses and retard or impair the eradication of brain invading microbes. It is 
intriguing reminder that type I IFN has been shown to increase autophagy, an emerging 
100 
 
antiviral defense mechanism of neurons297. Moreover, autophagy-lysosome defects 
have been reported to occur early in the AD pathogenesis298. Therefore, decreased 
signaling by IFN molecules in the AD brain might reverberate upon other antimicrobial 
mechanisms and increase neuronal susceptibility to infections and neuroinflammation.  
Possible regulatory mechanisms of the innate immune genes upon Aβ peptide 
expression in normal or AD brains have been poorly explored. However, it cannot be 
excluded that Aβ peptide might be an emergency defensive mechanism compensating 
the declining expression of other specialized defensive immune genes in the ageing 
brain. 
Among the genetic risk factors for AD, the presence of the APOE ε4 allele plays a 
major role and the APOE status might influence different mechanisms involved in 
neurodegeneration. Here, we showed that brain hippocampal expression of MED23, 
IL28B and IFN-α mRNAs in APOE ε4 carrier AD patients was significantly decreased.  
It is known that APOE affects immunity, since increased systemic proinflammatory 
states and altered immune responses have been found in APOE deficient mice299,300. 
Therefore, we speculate that, at least, part of the increasing AD risk effect of the APOE 
ε4 allele might be mediated by a negative influence on the brain immune efficiency in 
selected CNS areas, such as the hippocampus, where replicating neurons301 might be 
more susceptible to virus infections or microbial products/toxins.  
Some studies have suggested that in people carrying the APOE ε4 allele and, 
therefore, predisposed to develop AD, occurrence of HSV-1 infection was increased302-
304. However, this correlation was not always confirmed305. APOE seems to affect the 
outcome of different infections303,306 and, interestingly, APOE ε4 is also a risk factor for 
cold sores307. Animal studies demonstrated that  APOE4/4 mice had an impaired 
microglia immune functionality308 and ApoE4 presence also influenced the viral load in 
the brain309. In a subsequent study, Burgos et al. showed that during acute infection 
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with HSV-1, ApoE4 was more efficient than ApoE3 in promoting viral colonization of the 
brain144. 
To explore the influence of individual genetic background on the observed impaired 
expression of antiviral response genes in AD brains, we have stratified their gene 
expression data with SNPs genotypes of IRF7 (rs6598008), MED23 (rs3756784) and 
IL28B (rs12979860).  
The presence of GA and AA genotype in the upstream IRF7 variant (rs6598008) was 
associated with decreased expression, in the hippocampus, of IRF7, MED23, IL28B 
and IFN-α, which are all involved in the innate immune control of HSV-1 infection196. 
Therefore, we suggest that AD patients with A allele for IRF7 rs6598008 may be more 
prone to deficient innate immune response and predisposed to brain infections with 
severe course leading to neurodegeneration.  
Individual genetic variations as APOE ε4 and IRF7 SNP (rs9568008) might be relevant 
in affecting antiviral gene responsiveness in the presence of specific stimuli as 
microbial infections.  
Susceptibility to complex heterogeneous diseases, like AD, depends on both genetic 
predisposition and exposure to environmental factors, with interactions between the 
two components that likely contribute substantially to the degree of disease risk310,311. 
However, the extent and mechanisms by which common human genetic variants affect 
the host response to environment factors remain inadequately explored and have been 
difficult to detect in clinical studies310,312. 
A minority of hippocampal AD samples included in this study showed up-regulation of 
MED23, IL28B and IFN-α genes. Such increased levels of mRNAs were not correlated 
with the presence of APOE ε4 or IRF7 A alleles (rs6598008). Therefore, AD shows 
heterogeneous alteration of IFN gene expression. Increased or decreased expression 
might be related with different clinical stages of the disease and parallel cycles of 
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reactivation and latency of neurotropic viruses. In this context, we hypothesize the 
existence of other candidate genetic variants potential associated in trans with type I 
and III interferon induction, in response to stimulus such as the persistence of virus 
and/or bacterial infections, and potentially linked to exacerbated brain immune actions. 
Alternatively, oral infections, that were reported as potential causes of BBB 
distruction135, might induce an exacerbated IFN-λ response of chroid plexus epithelial 
cells313 in the presence of neuro-invasive viruses, as those belonging to herpes family.  
In animal models, differences in treatment with various stimuli have revealed the 
existence of reQTLs314-317 (response expression Quantitative Trait Loci), defined as 
QTLs associated with the change in expression after stimulation. The reQTLs identified 
by Lee and colleagues provide genetic explanations for inter-individual variation in 
innate immune responses318. In particular, their study revealed the effects of a trans-
reQTL in the IRF7 locus on target antiviral genes in the context of a particular cell type, 
such as DCs, and in response to specific ligand, such as influenza virus. The changes 
in this immune response were, in turn, likely to affect organism’s phenotypes that are 
driven by the IFN module, including susceptibility to viral infections318. 
This work indirectly supports the notion that a defective brain response to 
microorganisms is a risk factor for developing clinical AD. Microbial infections may play 
a role in AD clinical progression and impaired innate immune responses against 
viruses, bacteria or their products may increase neurodegenerative mechanisms in the 
elderly. However, these preliminary results should be interpreted with caution and they 
should be replicated in a larger population of patients.    
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Effects of prenatal stress (PNS) on adult 
cognitive health 
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AD is probably best considered in a life-course framework, like other chronic diseases,  
with important influences beginning at conception and early-life moments. While most 
cases of AD occur at late onset and older ages, increasing evidences support the 
notion that the neurodegenerative alterations precede AD clinical manifestation by 
many decades319. Both genetic and environmental factors are involved in the onset of 
sporadic AD. Several epidemiological studies have indicated that environmental 
factors, such as chronic stress and stress-related disorders, can influence the 
progression of AD-related symptoms and pathologies205-207.   
AD mouse models at different life stages have demonstrated that stress exposure can 
alter the neuropathological process causing reduction of neurons in memory regions, 
along with increased deposits of Aβ peptide and hyperphosphorylated microtubule 
associated tau protein320-322. Contrary to infancy and adulthood mouse models, only 
few studies investigated the role of stress prenatally experienced on the development 
of AD319. 
There is growing evidence that proper organism development is strongly influenced by 
early-life environment323. It has been observed that infants with low birth weight and 
small head circumference are at higher risk of suffering coronary heart disease, 
hypertension, stroke, insulin resistance, diabetes and other diseases in adulthood324. 
According to this experimental evidences, Barker proposed the fetal origins hypothesis 
in which the intrauterine environment has significant impact on the development of 
chronic diseases325. Lahiri and colleagues suggested that many neurobiological 
disorders, including AD, share a similar mechanistic etiology: the Latent Early-life 
Associated Regulation or LEARn model126,221. Under LEARn, early-life stressors modify 
potential expression levels of disorder-associated genes in a latent manner. Latent 
changes in these genes are maintained by epigenetic mechanisms. This model makes 
the greatest allowance for sporadic appearance of a disorder, especially if it is actually 
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”many” or “n hit”, where “n” can be any number of individual risk factors, each with the 
potential to instil or activate a latent alteration326.  
Many studies have shown that stressful events during the intrauterine life can exert 
long-lasting effects on the brain by affecting the nervous, neuroendocrine and immune 
systems209-211. Moreover, studies in humans and rodents, revealed a clear impact of 
early-life stress on the development of neuropsychiatric disorders such as autism, 
mood disorders and schizophrenia208,327,328. Interestingly, few studies have also linked 
prenatal stress (PNS) to adult cognitive impairment214,215,329. 
Based on these grounds, we planned to get a deeper insight in the molecular 
mechanisms at the basis of potential cognitive impairment caused by prenatal stress in 
mice.   
In this study we investigated the effects of prenatal stress (PNS) on the onset and 
progression of AD-related behavioural deficits, focusing also on potential sex-
dependent differences. To address this problem, we assessed the consequences of 
PNS on adult behaviour in wild type (WT) and APP/PSEN1dE9330,331 (Tg) offspring, 
testing them for anxiety-related behaviour and for learning and recognition memory at 
six and nine months of age. 
PNS during late gestation (embryonic days 12.5 – 18.5) did not elicit anxiety-related 
behaviour during late adulthood. Indeed, the open-field test and the following analyses 
of locomotor, central and/or peripheral activities of WT and Tg offspring (male and 
female) did not reveal any significant differences between PNS and ctrl groups neither 
at six nor at nine months. Similarly, Sierksma et al. showed that anxious behaviour 
remained unchanged in both prenatally stressed male and female Tg offspring. On the 
other hand, other studies showed that PNS induces anxiety-traits in young adulthood in 
WT offspring and the discrepancy with our results might depend on the kind of PNS, its 
timing and on the age of the tested offspring332-335.  
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Furthermore, at six months we found that PNS exposure impaired significantly long-
term recognition memory performance only of Tg male offspring, affecting the onset of 
AD-related recognition memory deficit. The evidences of memory stress-damage in six 
month old mice, for which the AD has not entailed recognition memory deficit yet, was 
not observed in nine month old mice. The nine month mouse memory has been 
already damaged by the AD neurodegeneration, minimising therefore the gap between 
the stress-exposed and non-exposed stress animals. In summary, these data showed 
a decreasing tendency in novel object recognition in Tg males that have been 
prenatally stressed, while prenatal stress seems to exert a protective effect on 
recognition memory of APPswe/PSEN1dE9 females. 
These results are in line with Sierksma and colleagues who found that repetitive 
restraint stress during the first week of gestation exerted a sex-dependent effect on 
behaviour and AD-related neuropathology in APPswe/PS1dE9 mice. Prenatally 
stressed male offspring showed spatial memory deficits and a blunted HPA axis 
response, while female offspring showed increased depressive-like behaviour and 
improved spatial memory performance with a decrease in hippocampal plaque load214.  
According to our results, it has been shown that AD mouse models exposed to stress 
during various stages of life alter AD-related symptoms and pathology320-322,336-338. 
Restraint stress during adulthood resulted also in elevated hippocampal concentrations 
of Aβ40 and Aβ42, higher plaque deposition, and increased tau phosphorylation. In 
addition, these mice displayed augmented neuronal degeneration with concomitant 
cognitive deficits338-342. Furthermore, several animal studies showed that prenatal 
maternal stress correlates with a series of neurological impairments, such as 
cholinergic neuronal damage, cognitive decline, hippocampal neuronal loss, increased 
tau protein phosphorylation and Aβ peptide deposits343-345.  
As a part of this ongoing project, the next step will be neuropathological phenotyping, 
by determing hippocampal plaque load and intracellular Aβ, of the WT and Tg offspring 
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to assess whether impact of PNS on the onset of AD-related cognitive decline 
correlates with amyloid burden.  
Prenatal life is a critical period characterized by increased vulnerability to 
stressors213,346. The process by which perinatal life events can have long-term effects 
on physiological system has been described as perinatal programming. During the 
perinatal period, the HPA axis is particularly susceptible to programming by 
glucocorticoids (GCs) that are important for normal maturation of most fetal organs 
including the developing brain. Thus, GCs are prime candidates for perinatal 
programming347 and exposure of the developing fetus or neonate to these 
glucocorticoid signals in excess or at an incorrect stage of maturation might lead to 
substantial alterations in normal developmental trajectories, resulting in altered 
physiological function throughout life and pathology in some circumstances348,349. In the 
brain, excess exposure to GCs leads to cognitive decline and has been associated with 
hippocampal neuron endangerment, dendritic atrophy and synaptic loss350,351. 
To find out PNS early target genes in the brain and to shed light on neurodevelopment 
trigger mechanisms of the cognitive impairment caused by PNS in APP/PS1 offspring, 
PNS neurobiological effects on WT E18.5 and P1 offspring were investigated. In 
particular, we focused on acute PNS effects on HPA axis function and brain gene 
expression. 
We found a different PNS influence on HPA axis between male and female WT 
offspring. PNS led to enhanced embryonic female HPA axis stress-response and to 
increased P1 male basal HPA activity, and this could result in an impaired 
programming of HPA function. It is important to consider that several confounding 
factors are present in the literature on this field. Within a given species, the stress-
timing, -dose and –source often differ among studies. The stage of development at 
which the outcome is measured and the sex of the offspring are other critical factors211. 
108 
 
All of these aspects will lead to differences in the measured outcomes and the 
presence of such confounding factors clearly require further repetition of the same 
experiment in order to improve the validity of our results. 
PNS consequences on brain gene expression of WT E18.5 and P1 offspring were 
different depending on the brain region, timing and sex. PNS significantly affected gene 
expression profiles of hippocampus only in P1 female offspring. The hippocampus is 
crucial for learning and memory processes. The susceptibility of the developing 
hippocampus to increased levels of GCs is linked to the high expression levels of their 
receptors209,211,319. We observed significant down-regulation of mineralcorticoid receptor 
(MR), DNA methyltransferase 1 (DNMT1) and of chemokine C-X3-C motif receptor 1 
(CX3CR1) genes and up-regulation of histone deacetylase-1 (HDAC1) gene in P1 
female offspring prenatally exposed to stress.  
The hippocampal decrease of MR mRNA expression of PNS P1 female WT offspring 
might be involved in feedback control of HPA axis during stress mediating alterations in 
glucocorticoid feedback sensitivity. Historically, because of different affinities for GCs, 
MR was considered important in regulating basal HPA activity, with GRs being 
occupied under conditions of elevated GCs (e.g. after stress); however, more recent 
evidences indicate that both receptor types are involved in HPA axis feedback control 
during stress204,352,353. The mechanisms reducing hippocampal MR mRNA expression 
in PNS mice are not defined; it is likely that increased levels of in utero corticosterone 
might affect MR gene promoter by influencing its expression. Whether PNS leads to 
MR gene methylation, as proposed for early-life programming of the GR gene244, is still 
far to be understood354.  
Different studies have linked PNS to impairments in adult cognitive heath, but little is 
known about the effects of PNS on epigenetic regulation despite prenatal life being a 
critical period for the programming of the epigenome355. DNA methylation players, 
including DNMT1, have a fundamental role in pre- and post-natal neurodevelopment356-
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360. In dividing cells, DNMT1 ensures that the parental DNA methylation pattern is 
maintained in the daughter cells, while in adult CNS neurons it is required for synaptic 
plasticity, learning and memory357. An histone modifying enzyme shown to interact with 
DNMT1 is HDAC1361. Fuks and colleagues identified a transcriptional repression 
domain in DNMT1 that functions, at least partly, by recruiting HDAC1 and they 
suggested that the process of DNA methylation mediated by DNMT1 may depend on 
or generate an altered chromatin state via histone deacetylase activity361. Akhtar et al. 
proposed that HDAC1, which is predominantly expressed in neural progenitor cells and 
glia362, together with HDAC2 forms a developmental switch that controls synapse 
maturation and function acting in a manner dependent on the maturational states of 
neuronal networks363. Our data have shown a PNS-induced altered expression of 
DNMT1 and HDAC1 genes in hippocampus of P1 female WT offspring and we 
hypothesize that PNS could affect or modulate synapse development during perinatal 
life modifying their expression. Evidence is accumulating regarding the opposite effects 
of PNS in males and females208,209,211,364, but the precise molecular mechanism 
underlying this sex-dependent difference is still unknown. The difficulty to unravel this 
mechanism is then increases by the fact that in the few studies found in the literature, 
researchers do not differentiate PNS effects according to the sex of the 
offspring215,335,357,363. 
Microglia were found to be crucial for the elimination of redundant dendritic spines by 
phagocytosis during brain development365. This so-called “synaptic pruning” is 
necessary for the proper formation and maturation of neural circuits and it is thought to 
involve CX3CL1, expressed by neurons during synapse maturation, and its receptor 
CX3CR1 on microglia365. However, the mechanisms that underlie microglial–synapse 
or microglial–axonal interactions remain unsolved96. CX3CR1 gene was found to be 
up-regulated in the hippocampus of PNS P1 female WT offspring. Matcovitch-Natan  et 
al. have identified a stepwise developmental program of microglia in synchrony with the 
developing brain and suggested that genetic or environmental perturbations of these 
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pathways can disrupt stage-specific functions of microglia and lead to loss of brain 
homeostasis, which may be associated with neurodevelopmental disorders366. 
The trend resulting from different animals studies suggest that exposure to prenatal 
stress can lead to significant increases in microglial activity327,367,368.  Of these studies, 
the two by Diz-Chaves et al. found potentiated responses in prenatally stressed 
animals that were subsequently given an immune challenge in adulthood327,367. The 
effects of maternal/early-life stress on microglial activity closely resembled that caused 
by pathogenic immune challenge in rodents369,370. Such studies support the idea that 
stress leads to microglial priming. The initial prenatal stimulation primes microglia 
inducing an exaggerated microglia response to a second inflammatory stimulus371. This 
underlies the “n-hit” hypothesis of the LEARn model326 according to which early-life 
stress sensitises microglial cells so inducing an exaggerated microglial responsiveness 
to stress in late adolescence or adulthood. This abnormal microglial activity may lead to 
brain changes that underlie the development of CNS chronic diseases372. As 
demonstrated by the preclinical studies, many forms of psychosocial stress are able to 
stimulate microglial activity throughout the brain, and in several cases, prenatal stress 
exposure is sufficient to cause lasting changes in microglial response372.  
 
Based on collected data, we suggested that the molecular players of PNS 
consequences in the brain have to seek within microglial synaptic plasticity pathways 
during neurodevelopment. Furthermore, in the attempt to discover the “hot spots” of 
PNS neurodevelopment impairment, it would be appropriate to focus on microglia cells 
and their role in synaptic plasticity both in female and male offspring. Future research 
will focus on the role of the same genes in synaptic remodelling and loss in 
APP/PSEN1dE9 offspring prenatally exposed to stress in order to test their roles in 
PNS-induced cognitive impairment.  
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Conclusion  
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AD is a complex multi-factorial disease in which several pathogenetic, clinical, 
environmental and stochastic factors are involved. 
It is on record that persistent virus infections and the immune competence decline with 
ageing might play a pivotal role in AD122.  In particular, defective immune defences 
against viruses may play a role in triggering chronic inflammatory responses and 
directly or indirectly activate neuroinflammation261. Here, we show that in patients with 
clinical and neurological defined diagnosis of AD, antiviral immune response appears 
to be defective in the majority of AD brain samples. Moreover, gene variants of APOE 
and IRF7 genes strongly affect mRNA levels of IRF7, MED23, IL28B and IFN-α in 
hippocampus area. This brain area shows an extensive and early neurodegeneration 
during AD clinical progression373. Therefore, these findings indirectly support the notion 
that microbial infections may play a role in AD clinical progression and deficient innate 
immune responses against viruses, bacteria or their products may increase 
neurodegenerative mechanisms in the elderly.  
The second part of this thesis shows that experimental animal research has the 
advantage of enabling strict control of environmental factors, such as prenatal stress 
(PNS) exposure, that might have a role in AD-related behaviour and 
neuropathology127,128,205. In particular, we investigated the long-term cognitive 
consequences of PNS in AD mice and the PNS-early neurobiological effects in wild 
type animals. As these, mice are a useful model to suggest that PNS affects the onset 
of cognitive deficit in AD mice in a sex-dependent manner. Our findings highlight that 
preventing the impairment of fetal neurodevelopment might be important for ensuring 
not only the future adult mental health374, but also for ageing well. Based on these 
results, AD is probably best considered in a life-course framework, with important 
influences beginning also at conception and early development.  
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In conclusion, the presented study gives new perspectives for prevention and treatment 
of the ageing-associated cognitive decline and AD. Protecting women from chronic 
stress during pregnancy, on the one side, and maintenance of efficient immune 
responses during ageing, on the other one, might slowdown neurodegenerative 
mechanisms associated with senile dementia and positively influence both prevalence 
and incidence of AD.  
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